






MASS DEWORMING FOR SOIL-TRANSMITTED HELMINTHS AND SCHISTOSOMIASIS AMONG 






Rehana Abdus Salam 
Paediatrics and Reproductive Health 
School of Medicine 











LIST OF TABLES 5 
LIST OF FIGURES 6 








CHAPTER 1: LITERATURE REVIEW AND CONCEPTUAL 
FRAMEWORK 11 
Epidemiology of Soil Transmitted Helminthiasis 11 
Epidemiology of Schistosomiasis 12 
Why is it a Public Health Concern? 15 
‘Deworming’: The Treatment as per the Existing Guidelines 16 
Existing Evidence on the Interventions 17 
Research and Implementation Gaps 21 
Conceptual Framework to Guide the Research 22 
Research Objectives 24 
CHAPTER 2: SYSTEMATIC REVIEW AND META-ANALYSIS TO 
ASSESS THE IMPACT OF MASS DEWORMING DURING 










Criteria for considering studies for this review 30 
Search methods for identification of studies 31 
Data collection and analysis 32 
Results 36 
Search results 36 
Characteristics of studies 37 
Quality of Studies 43 
3 
 
Summary of the Findings 52 
Discussion and Conclusions 54 
CHAPTER 3: SYSTEMATIC REVIEW AND META-ANALYSIS TO 
ASSESS THE EFFECTIVENESS OF INTERVENTIONS OTHER THAN 
DEWORMING FOR PREGNANT WOMEN AND WOMEN OF 
REPRODUCTIVE AGE ON MATERNAL, BIRTH AND NEWBORN 









Criteria for considering studies for this review 59 
Search methods for identification of studies 60 
Data collection and analysis 61 
Results 64 
Search results 64 
Characteristics of studies 64 
Findings 65 
Discussion and Conclusions 70 
Research Priorities 71 
CHAPTER 4: AN INDIVIDUAL PARTICIPANT DATA (IPD) META-
ANALYSIS TO IDENTIFY THE FACTORS THAT EXPLAIN THE 





Search methods 72 
Selection criteria 72 






Criteria for considering studies for this review 77 
4 
 
Search methods 78 
Data collection and analysis 80 
Results 83 
Search results 83 
Characteristics of studies 85 
Quality of Studies 90 
Contacting authors and yield of the studies 92 
Data Preparation: Missingness analysis 93 
Data Replications 94 
IPD feasibility and changes to the analysis model 95 
Main effects 97 
Effect modifier analyses 99 
Discussion and Conclusion 101 
CHAPTER 5: MASS DEWORMING DURING PREGNANCY: FROM 
POLICY TO IMPLEMENTATION 103 
Abstract 103 
Mass Deworming: WRA remains a neglected group 104 
Current guidelines 105 
Challenges with the current recommendations 105 
Economic Perspective 107 
What’s the way forward? 109 
CHAPTER 6: OVERALL CONCLUSIONS 112 
Abstract 112 
Summary of main results 113 
Overall completeness and applicability of evidence 113 
Quality of the evidence 114 
Limitations and potential biases in the review process 114 
Agreements and disagreements with other studies or reviews 114 
Implications for policy 115 
Implications for research 115 
APPENDICES 116 
Appendix 1: Search Strategy 116 
Appendix 2: Characteristics of the Excluded Studies 119 
Appendix 3: Search Strategy 120 
Appendix 4: Characteristics of the Excluded Studies 121 





List of Tables 
 
Table 1.1: Existing deworming guidelines by the World Health Organization 
Table 2.1: Subgroups of WRA at risk of STH infection in 2015 
Table 2.2: Deworming drugs and co-interventions in included studies 
Table 2.3: Characteristics of Included Studies 
Table 2.4: Risk of bias for non-randomised studies 
Table 2.5: Summary of the findings table 
Table 3.1: Characteristics of the included studies 
Table 3.2: Associations between WASH exposures and worm burden 
Table 4.1: Eligibility for IPD 
Table 4.2: Characteristics of IPD eligible studies 
Table 4.3: Missing values for baseline variables 
Table 4.4: Missing values for endpoint variables 
Table 4.5: Standardized differences between published and reproduced results for outcome measures by 
eligible studies 
Table 4.6: Comparison of the original analysis plan and actual model employed 
Table 4.7: Impact of mass deworming on maternal anaemia 
Table 4.8: Mass deworming on T.Trichiura intensity (any infection) 
Table 4.9: Mass deworming on hookworm intensity (any infection) 
Table 4.10: Mass deworming on LBW 
Table 4.11: Mass deworming on preterm birth 
Table 4.12: Potential effect modification of mass deworming during pregnancy by baseline infection 
intensity, anaemia status, and BMI 














List of Figures 
 
Figure 1.1: Age-associated prevalence and intensity (faecal egg count) profiles of STH and 
schistosomiasis infections 
Figure 1.2: Worldwide distribution of STH 
Figure 1.3: Worldwide distribution of Schistosomiasis 
Figure 1.4: Conceptual framework 
Figure 2.1: Search flow diagram 
Figure 2.2: Risk of bias for the included trials 
Figure 2.3: Forest plot for the impact of mass deworming during pregnancy on maternal anaemia 
Figure 2.4: Forest plot for the impact of mass deworming on worm prevalence 
Figure 2.5: Forest plot for the impact of mass deworming during pregnancy on maternal haemoglobin 
Figure 2.6: Forest plot depicting the impact of mass deworming on birth weight 
Figure 2.7: Forest plot depicting the impact of mass deworming during pregnancy on LBW 
Figure 2.8: Forest plot depicting the impact of mass deworming during pregnancy on preterm birth 
Figure 2.9: Forest plot for the impact of mass deworming during pregnancy on perinatal mortality 
Figure 2.10: Forest plot for the impact of mass deworming on stillbirths 
Figure 2.11: Forest plot for the impact of mass deworming during pregnancy on neonatal mortality 
Figure 2.12: Forest plot for the impact of mass deworming during pregnancy on congenital abnormalities 
Figure 3.1: Transmission cycle 
Figure 3.2: Search flow diagram 
Figure 4.1: Search flow diagram 
Figure 4.2: Risk of bias for the included trials 














Soil transmitted helminthiasis (STH) and schistosomiasis during pregnancy can cause active and debilitating 
disease with adverse birth outcomes. A recent estimation suggests that approximately 688 million girls and 
women of reproductive age (WRA) are at risk of helminth infections; including 140 million pregnant and 
lactating women and another 108 million adolescent girls. Mass deworming is regarded as the most effective 
means of controlling morbidity and mortality with STH and schistosomiasis; however there are various factors 
that could potentially modify its effectiveness including baseline nutritional status, worm burden and 
concomitant interventions. Currently, it is difficult to establish whether mass deworming during pregnancy 
has beneficial effects under certain conditions and limited effects under others. 
Objectives  
1. To conduct a systematic review and meta-analysis on the impact of deworming during pregnancy. 
2. To conduct a systematic review and meta-analysis on the impact of interventions other than deworming; 
including water, sanitation and hygiene (WASH) interventions. 
3. To conduct an individual participants data (IPD) meta-analysis to identify the factors that explain variation 
in the effect estimates of mass deworming. 
4. To discuss the current guidelines on mass deworming, the challenges and the economic perspective of 
mass deworming for WRA. 
Methods 
To achieve the aforementioned objectives, following methodology was adopted: 
1. A systematic review and meta-analysis evaluating the effectiveness of mass deworming during 
pregnancy. 
2. A systematic review and meta-analysis evaluating the effectiveness of WASH interventions during 
pregnancy. 
3. An IPD meta-analysis to explore whether the effect of mass deworming during pregnancy varies with 





1. Findings from the systematic review assessing mass deworming during pregnancy suggest that it 
does not have any impact on maternal anaemia; however it significantly reduced the prevalence of 
STH and schistosomiasis. There was no impact of mass deworming during pregnancy on 
haemoglobin, birth weight, low birth weight (LBW), preterm birth, perinatal mortality, stillbirths, 
neonatal mortality and congenital abnormalities. 
2. Findings from the systematic review on interventions other than mass deworming among pregnant 
women and WRA suggest that the data are too scarce and of low quality to inform best practice. 
3. The IPD component of the thesis captured majority of the existing data (70% of the total potential 
participant population). 
4. Findings from the IPD analysis suggest that mass deworming during pregnancy is associated with 
reducing anaemia with no apparent impact on infection intensity, LBW and preterm birth. These 
analyses were limited by the availability of data for the impact by subgroups and effect modification. 
Further studies accounting for maternal baseline worm intensities, concomitant iron/folic acid 
supplementation and antenatal care coverage could change these findings. 
Conclusion 
Mass deworming remains the recommended strategy to prevent and treat STH and schistosomiasis; however 
deworming alone is insufficient to achieve improvements in all maternal and newborn health outcomes. It is 
essential to address other factors such as poor sanitation, food insecurity and malnutrition. There is a need 
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Chapter 1: Literature Review and Conceptual Framework 
Epidemiology of Soil Transmitted Helminthiasis  
The term ‘helminth’ means parasitic worms and soil transmitted helminthiasis (STH) are a group of diseases 
caused by infection with four intestinal parasites: Ascaris lumbricoides (roundworm), Trichuris trichiura (whip 
worm), Necator americanus (hookworm) and Ancylostoma duodenale (hookworm) (WHO, 2015). STH is 
transmitted through the eggs present in the faeces of an infected person which contaminate the soil in areas 
with poor water and sanitation facilities. Eggs of Ascaris and Trichuris mature in soil and infect other people 
when ingested through contaminated hands or food while the larvae of hookworms penetrate the skin of the 
person walking barefoot on contaminated soil.  
Around 25% of the world’s population (roughly about 1.5 billion people) is infected with one or more of STH 
with a disproportionately higher burden in low- and middle- income countries (LMICs) (Chan, Medley, 
Jamison, & Bundy, 1994). An estimated 438.9 million people were infected with hookworm in 2010; 819 
million with roundworms and 464.6 million with whipworm. STH altogether, contributed to a total of 4.98 
million years lived with disability (YLDs) (Pullan, Smith, Jasrasaria, & Brooker, 2014). Of these YLDs, 65% 
were attributable to hookworm, 22% to roundworm and the remaining 13% to whipworm. In terms of 
geographical distribution, around 67% of STH occurred in Asia contributing to 68% of the YLDs (Pullan et al., 
2014). Even within LMICs, the disease disproportionally affects the most marginalised population groups and 
appears to be predominantly affecting the poorest populations with lack of clean water, hygiene and sanitation 
facilities (Pullan, Smith, Jasrasaria, & Brooker, 2014; WHO 2019). Over 267 million preschool-age children 
and 568 million school-age children live in STH endemic areas and an estimated 4 million pregnancies a year 
are complicated by maternal hookworm infection alone (D. Bundy, Chan, & Savioli, 1995; WHO, 2005). An 
age related pattern is observed for the prevalence and intensity of STH and schistosomiasis (Figure 1.1). 
Roundworm and whipworm reaches maximum prevalence (prevalence of a parasite species is defined as 
the percentage of hosts infected by that species)  before five years of age, while maximum prevalence of 
hookworm and schistosome infections is usually attained in adolescence or in early adulthood. High intensity 
(intensity of the infection is defined as the mean number of parasite eggs, oocysts or larvae per infected host) 
infestation with round worm and whip worm are common among children aged 5 to 10 years, while hookworm 
infections reaches maximum intensity from 20 to 25 years of age (Bethony et al., 2006; Hotez & Cerami, 
1983; Hotez et al., 2006). 
12 
 
Epidemiology of Schistosomiasis 
Schistosomiasis is also a parasitic disease caused by blood flukes of the genus Schistosoma. Six species of 
schistosomes are responsible for infection in humans: Schistosoma mansoni, S.haematobium, S. japonicum, 
S. intercalatum, S. guineensis and S. mekongi; S. haematobium and S. mansoni are predominant causes of 
disease (WHO, 2015). When infected persons’ faeces containing parasite eggs are released in fresh water, 
these eggs hatch and the subsequent larvae infect susceptible snail hosts. Parasites undergo asexual 
multiplication in snails and release another larval stage into water. These larvae penetrate the skin during 
contact with infested water and infect the human host during domestic, occupational and recreational contact 
with water. 
The distribution of schistosomiasis is focal, since transmission depends on specific snail hosts and human 
activities and the endemicity changes with the environment, water development schemes, migration, control 
interventions and snail host distribution. An estimated 249 million people required preventive chemotherapy 
for schistosomiasis in 2012, 93% of them in sub-Saharan Africa (WHO, 2015). Figure 1.2 and Figure 1.3 














Figure 1.1: Age-associated prevalence and intensity (faecal egg count) profiles of STH and 
Schistosomiasis infections 
 
Source: Hotez, P.J., et al., Helminth infections: soil-transmitted helminth infections and schistosomiasis. 2 ed. Disease Control Priorities in Developing Countries. 





Figure 1.2: Worldwide distribution of STH
 
Source: World Health Organization. Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected diseases 2015. World 
Health Organization, 2015 
 
 
Figure 1.3: Worldwide distribution of Schistosomiasis
 
Source: World Health Organization. Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected diseases 2015. World 




Why is it a Public Health Concern?  
STH and schistosomiasis are a major public health concern since these parasites feed on blood and hence 
contribute to anaemia (P. Hotez & Cerami, 1983; Torlesse & Hodges, 2000). Anaemia is one of the most 
common side effects of infection with STH or schistosomes, due to blood loss in the intestine or urinary tract. 
STH may also lead to haemorrhage by releasing anticoagulant compounds, thereby leading to iron-deficiency 
anaemia. Although iron-deficiency anaemia is multifactorial, hookworm infection is an important contributory 
factor in endemic areas, especially among women of reproductive age (WRA). An analysis on anaemia 
epidemiology based on data from the Global Burden of Diseases, Injuries and Risk Factors (GBD) 2010 
Study suggested that hookworm and schistosomiasis were among the top ten causes of anaemia among 
females in 2010 (Kassebaum et al., 2014). It is the leading cause of pathological blood loss in tropical and 
subtropical regions (Pawlowski, Schad, & Stott, 1991). Additionally, STH and schistosomiasis often occur 
with co-infections in areas where malnutrition is already prevalent (Martin, Blackwell, Gurven, & Kaplan, 
2013).  
Infection during pregnancy leads to an added demand for nutrients that are critical for fetal growth and 
development (Abrams & Miller, 2011; Blackwell, Snodgrass, Madimenos, & Sugiyama, 2010). Hookworms, 
in particular, along with other STH and schistosomes, have been associated with reductions in haemoglobin 
and iron deficiency during pregnancy (Gyorkos, Gilbert, Larocque, & Casapía, 2011; Larocque, Casapia, 
Gotuzzo, & Gyorkos, 2005; Muhangi et al., 2007; Ndyomugyenyi, Kabatereine, Olsen, & Magnussen, 2008q; 
Nurdia, Sumarni, Hakim, & Winkvist, 2001). Schistosomiasis could also lead to hepatic fibrosis and the 
associated increased risk of oesophageal varices among pregnant women at approximately the same rates 
as non-pregnant individuals. Women in LMICs are especially prone to these infections and their 
consequences since they may be pregnant or lactating for as much as half of their reproductive lives ("Report 
of the WHO informal consultation on hookworm infection and anaemia in girls and women," 1994). Estimates 
indicate that over 50% of the pregnant women residing in LMICs have iron-deficiency anaemia (Mason, 2000; 
WHO, 1997). There is a direct association between the intensity of STH infection, blood loss and consequent 
anaemia, especially for hookworms (Bundy et al., 1995; Chan et al., 1994;  Larocque et al., 2005). The 
association between anaemia during pregnancy and adverse pregnancy outcomes, including low birth weight 
(LBW), preterm birth, perinatal mortality and infant survival have already been documented (Rahman et al., 
2016; Sifakis & Pharmakides, 2000). Furthermore, the chances of favourable pregnancy outcomes are 
reduced by 30% to 45% in anaemic mothers, with their infants having less than one half of normal iron 
reserves (Rahman et al., 2016). 
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‘Deworming’: The Treatment as per the Existing Guidelines  
Mass deworming (also called preventive chemotherapy, is the process of treating large numbers of people 
in areas with a high prevalence of these conditions) along with the water, sanitation and hygiene (WASH) 
interventions are generally accepted as effective measures to prevent and treat STH and Schistosomiasis 
(WHO, 2017). The World Health Organization (WHO) recommends mass deworming for STH and 
Schistosomiasis depending on prevalence of worm infection. Preventive chemotherapy (deworming), using 
single-dose albendazole (400 mg) or mebendazole (500 mg), is recommended as a public health intervention 
for pregnant women, after the first trimester, living in areas where both:  
(i) the baseline prevalence of hookworm and/or T. trichiura infection is 20% or higher among 
pregnant women, and  
(ii) anaemia is a severe public health problem, with a prevalence of 40% or higher among pregnant 
women, in order to reduce the worm burden of hookworm and T. trichiura infection (WHO, 2017).  
For schistosomiasis, annual treatment with praziquantel in high risk communities (>50%) and once every two 
years in medium risk (>10% and <50%) is recommended and women can be treated with praziquantel at any 
stage of pregnancy and lactation (WHO, 2006). In addition to deworming; education on health and hygiene 
and provision of adequate sanitation is also recommended. Table 1.1 summarises the existing deworming 
guidelines by the WHO.  
Deworming is regarded as the most effective means of controlling morbidity and mortality with STH and 
Schistosomiasis. Preventive chemotherapy (either alone or in combination) has been used as a public heath 
tool for preventing morbidity due to infection usually with more than one helminth at a time since many of the 
anthelminthic drugs are broad spectrum. In 1994, the WHO convened an informal consultation on hookworm 
infection and anaemia in girls and women, which promoted the use of anthelminthic drugs in pregnancy after 
the first trimester in areas where these infections are endemic and where anaemia is prevalent, but it also 
recommended evaluation of the long-term safety, particularly in terms of birth outcomes (WHO, 1994). 






Table 1.1: Existing Deworming Guidelines by the World Health Organisation 
 Parasite Species Common 
Name 










Roundworm Preschool and school-age 
children; women of 
childbearing age (including 
pregnant women in the 2nd 
and 3rd trimesters and 
lactating women); adults at 
high risk in certain 






































School-age children; adults 
considered to be at risk, from 
specific groups (pregnant and 
lactating women; groups with 
occupations involving contact 
with infested water, such as 
fishermen, farmers, irrigation 
workers, or women in their 
domestic tasks) to entire 












Existing Evidence on the Interventions 
Currently, no vaccines are licensed for STH and schistosomiasis; and deworming with anthelminthic drugs 
is endorsed as an effective strategy for the prevention and control along with appropriate WASH interventions 
and education (WHO, 1994, 2017). A Cochrane review evaluating the impact of deworming given after the 
first trimester of pregnancy (including four trials with 4265 participants) suggested that a single dose of 
anthelminthic in the second trimester of pregnancy was not associated with any impact on maternal anaemia 
in the third trimester (risk ratio (RR): 0.94; 95% Confidence Interval (CI): 0.81, 1.10; 3266 participants; four 
trials; low quality evidence). The review did not find any impact on LBW (RR 1.00; 95% CI: 0.79, 1.27; 3255 
participants; three trials; moderate quality evidence); preterm birth (RR 0.88; 95% CI 0.43 to 1.78; 1318 
participants; two trials, moderate quality evidence); and perinatal mortality (RR 1.09; 95% CI 0.71 to 1.67; 
3385 participants; two trials; moderate quality evidence) (Salam, Haider, Humayun, & Bhutta, 2015). The 
review concludes that the existing evidence is insufficient to recommend use of anthelminthic drugs for 
pregnant women. Furthermore, the review conclusions stated that there is a need for more robust, large scale 
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randomised controlled trials to establish the benefit of anthelminthic treatment during pregnancy. There are 
no existing systematic review on schistosomiasis treatment in pregnancy, however, an existing Cochrane 
review evaluating the impact of drugs to treat schistosomiasis in general population (including 52 trials) 
suggested that praziquantel 40 mg/kg is effective as the standard treatment for S. mansoni infection while 
oxamniquine, a largely discarded alternative (due to a lack of current consensus on the optimal dosing 
regimen) also appeared to be effective (Danso-Appiah, Olliaro, Donegan, Sinclair, & Utzinger, 2013). Another 
Cochrane review evaluating the effectiveness of drugs (including 30 trials with 8165 participants) for urinary 
schistosomiasis in general population suggested that praziquantel 40 mg/kg was the most studied drug for 
treating urinary schistosomiasis, and had the strongest evidence base (Kramer, Zhang, Sinclair, & Olliaro, 
2014). The review concluded that there is a need for future research on the combination of drugs to treat 
schistosomiasis using rigorous, adequately powered trials with standardized outcome measures. 
For interventions other than deworming, existing literature highlights the lack of high quality evidence (Grimes 
et al., 2014; Strunz et al., 2014). One review (including 36 studies) suggested that availability of sanitation 
was associated with reduced infection with STH (odds ratio (OR): 0.49, 95% CI: 0.40, 0.60; 13 studies); while 
use of sanitation had a non-significant impacts on whipworm (OR: 0.54, 95% CI: 0.28, 1.02; 5 studies), 
hookworm (OR: 0.63, 95% CI: 0.37, 1.05; 5 studies), and roundworm (OR: 0.78, 95% CI: 0.60, 1.00; 8 
studies). Sanitation availability and use combined was associated with reduced prevalence of STH (OR: 0.51, 
95% CI: 0.44, 0.61; 15 studies), roundworm (OR: 0.54, 95% CI: 0.43, 0.69; 32 studies), whipworm (OR: 0.58, 
95% CI: 0.45, 0.75; 24 studies) and hookworm (OR: 0.60, 95% CI: 0.48, 0.75; 24 studies) (Ziegelbauer et al., 
2012). Another review including 94 studies suggested that use of treated water was associated with lower 
odds of overall STH infection (OR: 0.46, 95% CI: 0.36, 0.60; 3 studies) (Strunz et al., 2014). Piped water 
access was associated with lower odds of roundworm (OR: 0.40, 95% CI: 0.39, 0.41; 4 studies) and 
whipworm infection (OR: 0.57, 95% CI: 0.45, 0.72; 3 studies), but not any STH infection (OR: 0.93, 95% CI: 
0.28, 3.11; 5 studies). Access to sanitation was associated with decreased likelihood of infection with any 
STH (OR: 0.66, 95% CI: 0.57, 0.76; 8 studies), whipworm (OR: 0.61, 95% CI: 0.50, 0.74; 7 studies), and 
roundworm (OR 0.62, 95% CI 0.44, 0.88; 6 studies), but not with hookworm infection (OR: 0.80, 95% CI: 
0.61, 1.06; 6 studies). Wearing shoes was associated with reduced odds of hookworm infection (OR: 0.29, 
95% CI: 0.18, 0.47; 5 studies) and infection with any STH (OR: 0.30, 95% CI: 0.11, 0.83; 3 studies). Hand 
washing, both before eating (OR: 0.38, 95% CI: 0.26, 0.55; 3 studies) and after defaecating (OR: 0.45, 95% 
CI: 0.35, 0.58; 3 studies), was associated with lower odds of roundworm infection. Soap use or even 
availability was significantly associated with lower infection with any STH (OR: 0.53, 95% CI: 0.29, 0.98; 3 
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studies), as was hand washing after defaecation (OR: 0.47, 95% CI: 0.24, 0.90; 5 studies) (Strunz et al., 
2014).  
One systematic review evaluated the impact of community based packaged delivery of interventions including 
health education to promote general hygiene and sanitation along with drug administration, iron and β-
carotene supplementation, snail control, constructing latrines, eliminating cattle from the residential areas, 
staff training, and community mobilization (Salam, Maredia, Das, Lassi, & Bhutta, 2014). The findings from 
this review were based on 32 studies and suggested that community based interventions (CBIs) are 
associated with reduced prevalence of STH (RR: 0.45, 95% CI: 0.38, 0.54) and schistosomiasis (RR: 0.40, 
95% CI: 0.33, 0.50). CBIs were also associated with improved mean haemoglobin (standard mean difference 
(SMD): 0.34, 95% CI: 0.20, 0.47) and reduced anaemia prevalence (RR: 0.90, 95% CI: 0.85, 0.96). However, 
there was no clear impact on ferritin, height, weight, LBW or stillbirths. A recent feasibility modelling study 
suggested that the most important determining factors in the control of STH were underlying intensity of STH 
transmission, current implementation of control programmes for neglected tropical diseases, and whether 
countries receive large-scale external funding and have strong health systems. However it will require a 
collaborative approach including a clean environment, appropriate delivery platforms and strong political will 













Table 1.2: Summary of the Existing Evidence 
Interventions Review Details Outcome 
Deworming for STH in pregnant women 
(Salam et al., 2015) 
4 trials, 4265 
participants 
Maternal anaemia: RR: 0.94, 95% CI: 0.81 to 1.10; 3266 participants; 4 
trials 
Low birth weight: RR: 1.0, 95% CI: 0.79 to 1.27; 1290 participants; 3 
trials 
Preterm birth: RR: 0.88, 95% CI: 0.43 to 1.78; 1318 participants; 2 trials  
Perinatal mortality: RR: 1.09, 0.71 to 1.67; 3385 participants; 2 trials 
Deworming for STH in children with 
known infection (Welch et al., 2016) 45 trials: one trial 
had over one 
million children, 
and the remaining 
included 67,672 
participants 
Haemoglobin: RR: 0.1, 95% CI: -0.65 to 0.86; 247 participants; 2 trials  
Weight gain: 0.2 to 1.3 kg higher; 627 participants; 5 trials 
Deworming for STH in children through 
community deworming programs  (Welch 
et al., 2016) 
Weight gain: SMD: 0.08, 95% CI: -0.11 to 0.27; 38392 participants; 10 
trials 
Height: SMD: 0.02, 95% CI: -0.14 to 0.17; 7057 participants; 7 trials 
Haemoglobin: SMD: 0.02, 95% CI: -0.08 to 0.04; 3595 participants; 7 
trials 
Mortality: RR: 0.95, 95% CI: 0.89 to 1.92; 1005135 participants; 3 trials 
Availability of sanitation (Ziegelbauer et 
al., 2012) 
36 studies 
(including 1 trial) 
A. lumbricoides: OR: 0.46, 95% CI: 0.33 to 0.64; 24 studies 
T. trichiura: OR: 0.56, 95% CI: 0.46 to 0.70; 19 studies 
Hookworm: OR: 0.58, 95% CI: 0.45 to 0.76; 19 studies 
Use of sanitation (Ziegelbauer et al., 
2012) 
 
T. trichiura: OR: 0.54, 95% CI: 0.28 to 1.02; 5 studies  
Hookworm: OR: 0.63, 95% CI: 0.37-1.05; 5 studies 
A. lumbricoides: OR: 0.78, 965% CI: 0.60 to 1.0; 8 studies 
Sanitation availability and use 
(Ziegelbauer et al., 2012) 
 
T. trichiura: OR: 0.58, 95% CI: 0.45 to 0.75; 24 studies 
Hookworm: OR: 0.60, 95% CI: 0.48 to 0.75; 24 studies 
A. lumbricoides: OR: 0.54, 95% CI: 0.43 to 0.69; 32 studies 
Piped water use (Strunz et al., 2014) 
 94 studies 
(including 5 trials) 
STH infection: OR: 0.93, 95% CI: 0.28 to 3.11; 5 studies 
A. lumbricoides: OR: 0.40; 95% CI: 0.39 to 0.41; 4 studies 
T. trichiura: OR: 0.57, 95% CI: 0.45 to 0.72; 3 studies 
Treated water use (Strunz et al., 2014)  STH infection: OR: 0.46, 95% CI: 0.36 to 0.60; 3 studies 
Wearing shoes (Strunz et al., 2014)  
Hookworm: OR: 0.29, 95% CI: 0.18 to 0.47; 5 studies 
STH infection: OR: 0.30, 95% CI: 0.11 to 0.83; 3 studies 
Soap availability/use (Strunz et al., 2014)  STH infection: OR: 0.53, 95% CI: 0.29 to 0.98; 3 studies 
Hand washing before eating (Strunz et 
al., 2014) 
 A. lumbricoides: OR: 0.38, 95% CI: 0.26 to 0.55; 3 studies 
Hand washing after defaecation (Strunz 
et al., 2014) 
 
A. lumbricoides: OR: 0.45, 95% CI: 0.35 to 0.58; 3 studies 
STH infection: OR: 0.47, 95% CI: 0.24 to 0.90; 5 studies 
Sanitation access (Strunz et al., 2014)  
STH infection: OR: 0.66, 95% CI: 0.57 to 0.76; 8 studies 
T. trichiura: OR: 0.61, 95% CI: 0.50 to 0.74; 7 studies 
A. lumbricoides: OR: 0.62, 95% CI: 0.44 to 0.88; 6 studies 




Research and Implementation Gaps 
While WASH and deworming are generally accepted as effective interventions to disrupt STH and 
schistosomiasis transmission, there is a great deal of heterogeneity in reported effect estimates from the 
existing systematic reviews. Furthermore, the effectiveness of mass deworming in improving various 
maternal and child health outcomes is a current source of debate (Turner et al., 2015). Critical appraisal of 
existing studies suggests that these studies fail to account for various factors that could modify the 
effectiveness of deworming including nutritional status, type of infection, worm burden and other concomitant 
interventions (Barry, Simon, Mistry, & Hotez, 2013; Turner et al., 2015). I joined the author team of the 
Cochrane systematic review evaluating deworming in the second trimester of pregnancy in 2015 (the protocol 
for this review was first published in 2005; and the review was first published in 2009. The most recent update 
of this review in 2015 concluded that there was insufficient evidence to recommend deworming in pregnancy 
with no impact on maternal anaemia, LBW, preterm birth and perinatal mortality (Salam, Haider, Humayun, 
& Bhutta, 2015). However this review focused only on STH and did not assess the effectiveness of deworming 
based on baseline morbidity and nutritional status. The review also did not report worm burden. The most 
recent Campbell systematic review and network meta-analysis with 47 randomised trials and over one million 
children, found little to no overall effect on growth, attention and school attendance (Welch et al., 2016). 
These reviews were conducted at the study level, rather than using data for each individual participant, 
limiting the power to detect effect modification by individual participant characteristics. Such characteristics 
could potentially modify the effect of deworming including baseline nutritional status, type of STH infection, 
treatment protocol, worm burden and concomitant interventions (such as iron supplementation) (Barry et al., 
2013; Turner et al., 2015).  
Despite the availability of more recent global estimates on the burden and interventions for STH and 
schistosomiasis, additional research is needed to understand the factors that explain the variation in the 
effect estimates of recommended interventions to prevent transmission. Various factors that could potentially 
modify the effectiveness of deworming include baseline nutritional status (anaemia and body mass index 
(BMI)), type of STH infection, treatment protocol, worm burden (particularly intensity of infection) and 
concomitant interventions (such as iron supplementation and co-administration of other drugs such as 
praziquantel for schistosomiasis).  Currently, it is difficult to establish whether deworming during pregnancy 
has beneficial effects under certain conditions and limited effects under others, and there exists a possibility 
that it is only beneficial in women with very high parasite burdens, dietary insufficiencies, or both (Blackwell, 
2016). Importantly, there has been no comprehensive study of these potential sources of heterogeneity in 
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the effects of WASH and mass drug administration (MDA) on transmission of STH. Moreover, all intestinal 
worms are not the same; not all intestinal worms respond to the same deworming medication; and not all 
infested individuals exhibit the disease. Additionally, STH infections are not always symptomatic and not all 
who receive MDA will benefit equally and hence there is a need to understand potential targeting of such 
programs for the age groups at risk (for example pregnant women, adolescents and WRA) (Anderson, Turner, 
Truscott, Hollingsworth, & Brooker, 2015). A recent systematic review has also highlighted the scarcity of 
cost related data for STH programs, which is of prime importance in planning treatment frequency and 
targeting for STH and schistosomiasis interventions (Turner et al., 2015). Reinfection depends on the 
prevalence and intensity of infection as well as environmental factors such as the WASH practices in the 
community.  
Existing studies fail to account for various underlying host and environmental factors that modify the 
effectiveness of deworming. An objective assessment of sources of heterogeneity in existing studies as well 
as subsets of subjects with varied risks and responses is required to move the field forward. An individual 
participant data (IPD) meta-analysis would explore the question of whether mass deworming during 
pregnancy is more effective for subgroups of women defined by characteristics such as nutrition status and 
infection intensity. IPD meta-analysis refers to analysing data for each participant in the existing studies 
(Tierney, Pignon, et al., 2015; Tierney, Vale, et al., 2015). The term IPD refers to analysing data recorded for 
each participant in contrast to the aggregate study data in meta-analysis. The advantage of an IPD analysis 
over aggregate meta-analysis is that it has the potential to improve the quality of both the data and the 
analyses and consequently the reliability of the results (Tierney, Vale, et al., 2015). Furthermore, it also 
provides an opportunity to re-analyse the data for a range of other possibilities for example, investigating the 
treatment effects varying by participant characteristics which is not possible with the aggregate data (Riley, 
Lambert, & Abo-Zaid, 2010). An IPD approach could allow the evaluation of variation in effect estimates by 
various individual, socio-demographic and environmental factors in pregnant women that could potentially 
modify the effectiveness of deworming during pregnancy. This understanding could help develop targeted 
strategies to reach pregnant women with deworming and guide future deworming policies.  
Conceptual Framework to Guide the Research 
To guide the research, a conceptual framework was devised (Figure 1.4). The conceptual framework focuses 
on the direct (deworming) and indirect interventions (use of latrines, sewerage disposal, safe water, wearing 
shoes, hand washing before eating and after defecation, nutrition, food safety) for maternal STH and 
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schistosomiasis. Around these direct and indirect interventions to prevent and control STH and 
schistosomiasis, there are various environmental, socio-demographic, individual and intervention factors that 
could potentially have an impact on the direct and indirect interventions. The environmental factors include 
high worm burden, high endemicity of infectious disease, poor sanitation, poor hygiene, season and climatic 
variation. Among the socio-demographic factors are low socioeconomic status, poverty, lack of education, 
overcrowding, house construction, occupation and family size. The individual factors that could potentially 
have an impact include maternal anaemia, baseline under-nutrition and other infections (including malaria, 
human immunodeficiency virus (HIV) or any other co-infections). The factors specific to intervention include 
supervision, dosage, time of day, place of administration, co-interventions, access to intervention, 
intervention coverage, accessibility, infrastructure, acceptability, coverage and costs.  
The framework also highlights various delivery platforms to target women for STH and schistosomiasis 
prevention and management. These platforms mainly include community-based or health-facility based 
delivery mechanisms. Community based delivery of interventions comprise of interventions administered at 
the community level by lay community members who have received basic training. Infectious diseases control 
programmes are increasingly setting up community-based delivery strategies and interventions that utilize 
groups of trained, community-based volunteers when health facilities or staff are not available. Health facility 
based delivery utilises primary, secondary or tertiary care facilities to target the delivery of interventions. In 
the context of pregnant women, these facilities include antenatal care clinics.  
Finally the framework highlights the desired outcomes including reduced symptoms, reduced anaemia, 
improved nutritional status, reduced reinfection, reduced STH prevalence and intensity, BMI, fatigue and 
ability to work. These outcomes then lead to impacts including improved pregnancy outcomes, LBW, preterm 
birth, perinatal mortality and infant survival as a result of successful prevention and management of maternal 








Figure 1.4: Conceptual Framework 
 
Research Objectives 
Based on the highlighted research gaps, it is important to characterise factors that modify the effect of 
maternal deworming and WASH interventions on STH and schistosomiasis transmission and to quantify the 
effect of deworming efforts in this specific sub-population. This will be done through a global systematic 
review of existing studies using IPD meta-analysis. The broad objective of this research is to use IPD meta-
analysis to explore whether the effect of deworming among pregnant women vary with individual 
characteristics (nutritional status, anaemia), intensity of infection (as assessed by egg count), infection status 
(including species of worm), socioeconomic status, sanitation environment and co-interventions. Specific 






1. To conduct a systematic review and meta-analysis on the impact of mass deworming during 
pregnancy for STH and schistosomiasis on maternal, birth and newborn health outcomes. 
2. To conduct a systematic review and meta-analysis on the impact of WASH interventions for STH 
and schistosomiasis on maternal, birth and newborn health outcomes. 
3. To conduct an IPD meta-analysis to identify the factors that explain the variation in the effect 
estimates of recommended interventions for STH and schistosomiasis. 
4. To discuss the current guidelines on mass deworming, the challenges and the economic perspective 

















Chapter 2: Systematic review and meta-analysis to assess the impact of 




Mass deworming is recommended as an effective strategy to prevent and treat soil transmitted helminthiases 
(STH) and schistosomiasis. However there is a great deal of heterogeneity in the existing evidence and the 
effectiveness of mass deworming in improving various maternal and newborn health outcomes is a current 
source of debate. Furthermore, the long-term safety of mass deworming during pregnancy, particularly in 
terms of birth outcomes, remains less rigorously evaluated. The aim of this review is to evaluate the impact 
of mass deworming during pregnancy on maternal, birth and newborn health outcomes. 
Methods 
We conducted a systematic review and meta-analysis of mass deworming using any drug or a combination 
of drugs during pregnancy for STH and schistosomiasis compared to no mass deworming. We used a 
comprehensive search strategy to identify eligible studies regardless of date of publication, language, or 
publication status till March 2018. We assessed the quality of the included studies using the Cochrane risk 
of bias assessment tool and summarised the quality of evidence according to the outcomes as per the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. 
Findings 
A total of 16 studies (31 papers) including 45,710 pregnant women were included in this review; nine of the 
included studies were randomised controlled trials. Findings suggest that mass deworming during pregnancy 
does not have any impact on maternal anaemia (risk ratio (RR): 0.97, 95% confidence interval (CI): 0.89 to 
1.05; six trials; 6696 participants; moderate quality evidence). Mass deworming during pregnancy 
significantly reduced the prevalence of Ascaris (RR: 0.24, 95% CI: 0.19 to 0.29; three trials; 2328 participants; 
moderate quality evidence), S.japonicum (RR: 0.30, 95%CI: 0.21 to 0.42; one trial; 370 participants; moderate 
quality evidence) and S.mansoni (RR: 0.25, 95% CI: 0.16 to 0.38; one trial; 1003 participants; moderate 
quality evidence). There was no impact on any of the other outcomes including hookworm prevalence (RR: 
0.35, 95% CI: 0.11 to 1.10; five trials; 3299 participants; low quality evidence), Trichuris (RR: 0.68, 95% CI: 
0.50 to 0.92; four trials; 2690 participants; moderate quality evidence), haemoglobin (Hb) (mean difference 
(MD) 0.08 g/dL, 95% CI: -0.07 to 0.24; five trials; 5704 participants; low quality evidence); birth weight (MD: 
0.00 kg, 95% CI: -0.07 to 0.07; four trials; 3651 participants; moderate quality evidence); low birth weight 
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(LBW) (RR: 1.04, 95% CI: 0.84 to 1.29; four trials; 3625 participants; moderate quality evidence); preterm 
birth (RR: 0.80, 95% CI: 0.49 to 1.30; three trials; 1781 participants; moderate quality evidence); perinatal 
mortality (RR: 1.09, 95% CI: 0.71 to 1.67; two trials; 3385 participants; moderate quality evidence); stillbirths 
(RR: 1.83, 95% CI: 0.99 to 3.37; three trials; 3866 participants; moderate quality evidence); neonatal mortality 
(RR: 0.69, 95% CI: 0.39 to 1.22; three trials; 3822 participants; moderate quality evidence) and congenital 
abnormalities (RR: 1.09, 95% CI: 0.79 to 1.49; four trials; 4212 participants; moderate quality evidence). 
Subgroup analysis could not be conducted due to the limited number of studies included in the review and 
since an individual participant data analysis (IPD) was already planned to follow. 
Interpretation 
Mass deworming during pregnancy is associated with reducing worm burden; however there was no impact 

















The World Health Organization (WHO) identifies three population groups at high risk for soil transmitted 
helminthiases (STH) and schistosomiasis including school-age children, preschool children, and girls and 
women of reproductive age (WRA) (WHO, 2006). A recent estimation suggests that an estimated 688 million 
girls and WRA are at risk of STH infection; including 140 million pregnant and lactating women and another 
108 million adolescent girls (Mupfasoni et al., 2018). Table 2.1 specifies the numbers and percentages of 
subgroups of women at risk. Approximately 40 million WRA are infected with schistosomiasis (Friedman, 
Mital, Kanzaria, Olds, & Kurtis, 2007; Nour, 2010). Geographically, the WHO South-East Asia and African 
regions have the highest numbers of each WRA subgroup, accounting for 74.7% of all STH at-risk WRA 
(Mupfasoni et al., 2018). 
Table 2.1: Subgroups of WRA at risk of STH infection in 2015 (Mupfasoni et al., 2018) 
Subgroup Number at risk of STH 
infection 
Percentage at risk of STH 
infection 
Adolescent girls (15-19 years) 108 269 000 15.7 
Pregnant women (15-49 years) 69 463 000 10.1 
Lactating women (15-49 years) 69 463 000 10.1 
Non-pregnant, non-lactating 
adult women (20-49 years) 
440 947 000 64.1 
Total 688 142 000 100 
 
STH and schistosomiasis during pregnancy causes active and debilitating disease with adverse effects on 
birth outcomes and the infant’s developing immune system (Bustinduy, Stothard, & Friedman, 2017; Freer, 
Bourke, Durhuus, Kjetland, & Prendergast, 2017; Sanya, Nkurunungi, Andia Biraro, Mpairwe, & Elliott, 2017). 
STH (including Ascaris lumbricoides, Trichuris trichiura and the hookworms (Ancylostoma 
duodenale and Necator americanus)) and schistosomes (including  S.haematobium, S.mansoni, and S. 
japonicum) have been associated with reductions in haemoglobin and iron deficiency during pregnancy. 
Evidence suggests a direct association between the intensity of infection, blood loss and consequent adverse 
pregnancy outcomes including low birth weight (LBW), preterm birth, perinatal mortality and infant survival 
(Bundy et al., 1995; Chan et al., 1994; Gyorkos et al., 2011; Larocque et al., 2005; Muhangi et al., 2007; 
Ndyomugyenyi et al., 2008q; Nurdia et al., 2001). Women suffer considerably from female genital 
schistosomiasis that causes infertility, preterm labour, anaemia, menstrual disorders, and dyspareunia (Freer 
et al., 2017; Nour, 2010). 
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Currently, mass deworming is recommended as an effective strategy to prevent and treat STH and 
schistosomiasis. The most recent recommendations by the WHO on deworming among pregnant women 
(WHO, 2017) recommends preventive chemotherapy (deworming), using single-dose albendazole (400 mg) 
or mebendazole (500 mg), as a public health intervention for pregnant women including pregnant adolescent 
girls after the first trimester (in the second or third trimester), living in areas where both:  
(i) the baseline prevalence of hookworm and/or T. trichiura infection is ≥ 20% among pregnant 
women, and  
(ii) where anaemia is a severe public health problem, with a prevalence of ≥ 40% among pregnant 
women. 
For schistosomiasis, annual treatment with praziquantel in high risk communities (>50%) and once every two 
years in medium risk communities (>10% and <50%) is recommended. Women can be treated with 
praziquantel at any stage of pregnancy and lactation (WHO, 2006). 
Deworming drugs such as levamisole, mebendazole, albendazole, praziquantel and pyrantel have been 
reported to be efficacious with minimal side-effects but data about their use in pregnancy are scarce (WHO, 
1994, 2018). Adverse events associated with deworming in girls and women themselves have rarely been 
published, and usually only within the context of specific research studies (Keiser & Utzinger, 2008; 
Ndyomugyenyi, Kabatereine, Olsen, & Magnussen, 2008). However, no serious adverse events have been 
reported (Ndyomugyenyi et al., 2008a). Along with the concerns related to undue exposure to deworming 
drugs during pregnancy as a result of routine mass deworming and the potential adverse effects on the 
foetus, there is lack of evidence supporting the health benefits of treating during pregnancy on birth outcomes. 
More recently, issues related to limited efficacy profiles of albendazole, mebendazole, levamisole, and 
pyrantel pamoate have been raised with some evidence supporting co-administration of a some deworming 
drugs (Moser, Schindler, & Keiser, 2017; Palmeirim et al., 2018). Although mass deworming is regarded as 
the most effective means of controlling morbidity and mortality with STH and schistosomiasis; the long-term 
safety when administered during pregnancy, particularly in terms of birth outcomes has not been rigorously 
evaluated (WHO, 1994, 2018). Therefore, the aim of this review is to assess the impact of mass deworming 




The objective of this systematic review and meta-analysis is to assess the impact of mass deworming during 
pregnancy for STH and schistosomiasis on maternal, birth and newborn health outcomes. 
Methodology 
Criteria for considering studies for this review 
Types of studies 
We included primary studies using experimental or quasi-experimental study designs that allow for causal 
inferences. We included randomised controlled trials (RCTs), quasi randomised studies and controlled before 
after studies (CBA). We also included case-control and cross-sectional studies reporting associations 
between mass deworming during pregnancy and on maternal, birth and newborn health outcomes. We 
excluded case reports and case-series.  
Types of participants 
Participants were pregnant women receiving preventive or therapeutic deworming drugs for STH and 
schistosomiasis. 
Types of interventions 
We included mass deworming using any drug or a combination of drugs (including levamisole, mebendazole, 
albendazole, praziquantel and pyrantel) for STH and schistosomiasis with or without co-interventions 
compared to placebo or control (no mass deworming). Co-interventions could be food provision, micronutrient 
supplementation, iron and/or folic acid supplementation, hygiene interventions or education. We included 
studies where the co-interventions were similar in the intervention and control groups to assess the impact 
of mass deworming. 
Types of outcome measures 
The following primary and secondary outcomes were reported; however we did not use the list of outcomes 
as a criterion for inclusion: 
-Primary outcomes: 
 Maternal anaemia at term (defined as haemoglobin (Hb) less than 11 g/dL) 





 Maternal Hb at term  
 Maternal ferritin at term 
 Maternal anthropometric measures (including maternal weight, body mass index (BMI), gestational 
weight gain etc.)  
 Birth weight 
 Low birth weight (LBW) (defined as birth weight less than 2500 grams)  
 Preterm birth (defined as birth before 37 weeks of gestation)  
 Perinatal mortality (includes foetal death after 28 weeks of gestation and infant death that occurs at 
less than seven days of life)  
 Stillbirth (defined as a baby born with no signs of life at or after 28 weeks' gestation) 
 Congenital anomalies (defined as structural or functional anomalies (e.g. metabolic disorders) that 
occur during intrauterine life and can be identified prenatally, at birth or later in life) 
 Infant mortality (defined as the number of deaths among children under one year of age occurring 
among the live births in a given geographical area during a given year, per 1,000 live births occurring 
among the population of the given geographical area during the same year) 
Search methods for identification of studies 
We used a comprehensive search strategy to identify eligible studies regardless of the date of publication, 
language, or publication status till March 2018. The search strategy is attached as Appendix 1. 
Electronic searches  
We searched the following electronic databases: MEDLINE, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Latin-American and Caribbean System on Health Sciences Information (LILACS), 
Excerpta Medica dataBASE (EMBASE), the Cochrane Library, Global Health CABI and Centre for Agriculture 
and Biosciences (CAB) Abstracts. We searched websites of relevant organizations such as the WHO 
Neglected Tropical Diseases, World Bank and World Food Program.  
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Searching other resources 
We also contacted authors of studies and members of the study’s advisory board for any unpublished studies 
or grey literature reporting eligible studies. We checked the reference lists of relevant studies and reviews. 
We also searched for trials registered with ClinicalTrials.gov. 
Data collection and analysis  
Selection of studies  
Two reviewers independently assessed potential study eligibility using predefined screening criteria. Any 
studies considered obviously irrelevant from screening the titles and/or abstracts were excluded at the first 
level. Any uncertainties at the first level screening were re-assessed on the basis of full text in the second 
level of screening. For any discrepancies, study’s advisory group was contacted for the final decision. Any 
disagreements were resolved through discussion until a consensus was reached.  
Data extraction and management  
We extracted data from included studies on the following: 
 Background: time period when study took place, type of publication (e.g. full-text journal article, 
abstract, conference paper, thesis) and study country or countries. 
 Population and study setting: population age and setting. 
 Methods: study design, description of study arms, unit of allocation, sample or cluster size per study 
arm (for individually or cluster randomised trials respectively), start and end date, duration of follow 
up. 
 Participants: total number randomised, baseline characteristics, number of withdrawals, socio-
demographic data (if available).  
 Intervention group details: number randomised to group, description of intervention, co-interventions, 
duration and follow-up, timing and delivery of intervention. In case of studies with multiple intervention 
arms, we described all arms, while we reported the arms that met the inclusion criteria. 
 Comparison group details: number randomised to group, description of comparison, duration and 
follow-up, timing and delivery. 
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 Outcomes: measurement tool, total number in intervention and comparison groups, change indicated 
at each time point. In case if multiple measures are reported for the same outcome construct, we 
used the one pre-specified in protocol. 
 Any other information deemed relevant.  
Assessment of risk of bias in included studies  
We assessed the quality of the included studies using the Cochrane risk of bias assessment tool for the 
RCTs. The quality of the RCTs was assessed based on selection bias, performance bias, detection bias, 
attrition bias and reporting bias (Higgins, Altman, & Sterne, 2011).  For non-randomised studies, we used the 
Cochrane Effective Practice and Organisation of Care (EPOC) group criteria for risk of bias assessment 
(EPOC, 2015). Quality of non-randomised studies was assessed based on random sequence generation, 
allocation concealment, baseline outcome measurements similar, baseline characteristics similar, incomplete 
outcome data, knowledge of the allocated interventions adequately prevented during the study, protection 
against contamination, selective outcome reporting and other risk of bias. We summarised the quality of 
evidence according to the outcomes as per the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) criteria (Walker, Fischer-Walker, Bryce, Bahl, & Cousens, 2010). A grade of “high”, 
“moderate”, “low” and “very low” were used for grading the overall evidence indicating the strength of an 
effect on specific health outcome based on methodological flaws within the component studies, consistency 
of results across different studies, generalizability of research results to the wider patient base and how 
effective the treatments have shown to be (Balshem et al., 2011).  
Measures of treatment effect  
For each outcome, data were converted to the same format (e.g. means and standard deviations for 
continuous data), including appropriate conversion of scales such that an increase/decrease always indicates 
improvement or deterioration of an indicator. Dichotomous and continuous outcomes were analysed 
separately. For dichotomous outcomes, results were presented as summary risk ratios (RRs) with 95% 
confidence intervals (CI), whenever possible, in order to compare risk of the outcome between intervention 
and control groups. Continuous outcome data were presented as either a mean difference (MD), if outcomes 
were measured on the same scale, or a standardized mean difference (SMD), if outcomes were measured 
on different scales, with 95% CI.  
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Unit of analysis issues  
Separate meta-analysis was conducted for studies with separate study designs (RCTs and non-randomised 
studies). Special attention was given to cluster-randomised trials to ensure that clustering has been 
appropriately accounted for within the analysis of the primary study, such that study precision is not over or 
under-estimated within our analysis. We did not make any adjustments if authors had appropriately adjusted 
for cluster design already. 
One trial (Urassa et al., 2011) was cluster-randomised trial. We used the intra-cluster correlation coefficient 
(ICC) and the variance inflation factor to adjust the standard errors appropriately. Subsequently, effect sizes 
and standard errors were meta-analysed by using the generic inverse method (GIV).  
In order to take into account potential sources of dependency, we grouped studies in terms of their location, 
population and the intervention being evaluated (for e.g. different drugs) to ensure that there was no double 
counting of evidence when synthesizing results across studies. If there were multiple papers that described 
the same trial, these were combined and coded as a single study. 
For trials that included multiple intervention arms, we selected one pair (intervention and control) that satisfied 
the inclusion criteria of the review and excluded the rest. If more than two intervention groups met the eligibility 
criteria, then these groups were combined into a single pair-wise comparison group and data were 
disaggregated into corresponding subgroups, or these arms were separated into different forest plots to 
ensure that there is no double counting of participants.  
Dealing with missing data  
Where data were incomplete or in a form that could not be converted with the information available, we 
contacted the corresponding author for clarification or to obtain missing data. If authors accounted for missing 
data (i.e. multiple imputations), we used the adjusted data within our analysis. 
Assessment of heterogeneity  
Clinical and methodological heterogeneity was explored by assessing the similarities and differences in 
included studies' participants, interventions, outcomes, and methods. Statistical heterogeneity was assessed 
by visually inspecting forest plots, calculating the I2 statistic (>50% indicated substantial heterogeneity) and 
conducting a Chi2 test, where a p-value <0.1 was considered statistically significant. Sources of heterogeneity 
was explored using sub-group analysis (where possible). 
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Assessment of reporting bias  
If the number of studies was sufficient (>10), funnel plots were used to visually assess publication bias. This 
kind of bias is unlikely if data forms a symmetric inverted funnel shape around the mean effect estimate.  
Data synthesis  
Statistical analysis was carried out using Review Manager 5.3. For RCTs, we followed intention to treat (ITT) 
analysis. For comparable interventions and outcomes, we presented the synthesis of quantitative evidence 
through meta-analysis. Fixed effects meta-analysis was used where there was sufficient similarity between 
studies' populations and methods, such that it was reasonable to assume that studies are estimating the 
same treatment effect. Where there was enough heterogeneity between studies to expect that underlying 
treatment effects differ between studies, random effects meta-analyses was used. For random effects 
analyses, the DerSimonian and Laird method was applied to incorporate a measure of variation (Tau2) among 
intervention effects from different studies. For interpretation of results, overall effect estimates that had an 
associated p-value <0.05 were deemed statistically significant. Non-significant findings were also reported. 
Where possible, interaction tests were used to determine if there was a relevant difference in effect across 
sub-groups. We also examined the subgroups’ confidence intervals; non-overlapping intervals indicated a 
statistically significant difference between groups. 
Subgroup analysis and investigation of heterogeneity  
Depending on data availability, exploratory sub-group analyses was planned on the primary outcomes for 
the following variables, selected based on their potential to impact the intervention effect: 
 Baseline infection intensity (light versus moderate versus heavy) 
 Baseline nutritional status (anaemic versus non-anaemic, low BMI versus normal BMI) 
 Co-interventions 
An individual participant data analysis was also planned to follow this systematic review. The findings are 
reported in the following chapters. 
Sensitivity analyses  
Sensitivity analyses was conducted to determine whether the removal of studies with high risk of bias or the 





Figure 2.1 provides a search flow diagram. We identified a total of 23,406 record through the search strategy 
provided in Appendix 1. A total of 31 papers (Abel, Rajaratnam, Kalaimani, & Kirubakaran, 2000; Ács, 
Bánhidy, Puhó, & Czeizel, 2005; Adam, Elwasila, & Homeida, 2005; Atukorala, De Silva, Dechering, 
Dassenaeike, & Perera, 1994a; Christian, Khatry, & West Jr, 2004; De Silva, Sirisena, Gunasekera, Ismail, 
& De Silva, 1999; Deepti & Nandini, 2015; Elliott et al., 2007; Elliott, Mpairwe, et al., 2005; Elliott, Namujju, 
et al., 2005; Gyorkos et al., 2011; Gyorkos, Larocque, Casapia, & Gotuzzo, 2006; Renée Larocque et al., 
2006; Liabsuetrakul et al., 2009; Millard et al., 2014; Tehalia 2011; Mpairwe et al., 2011; Nampijja et al., 
2012; Juliet Ndibazza et al., 2012; J Ndibazza et al., 2010; Ndyomugyenyi et al., 2008a; Olveda et al., 2016; 
Torlesse & Hodges, 2000, 2001; Tweyongyere et al., 2009; Tweyongyere et al., 2011; Tweyongyere et al., 
2008; Tweyongyere et al., 2013; Urass, Nystrom, & Carlstedt, 2011; Villar, Dala, & Cardona, 1998; Webb et 
al., 2012; Webb et al., 2011) based on 16 studies were included based on the eligibility criteria. Appendix 2 
provides reasons for exclusion for the excluded studies.  





Characteristics of studies 
A total of 16 studies including 45,710 pregnant women were included in this review. Nine of the included 
studies were RCTs while seven were non-randomised studies. Studies were conducted in Hungary, India, 
Nepal, Pakistan, Philippines, Peru, Sierra Leone, Sri Lanka, Sudan, Tanzania, Thailand and Uganda between 
1994 and 2016. The deworming drugs provided in these studies included albendazole, mebendazole, 
praziquantel or a combination of these. A majority of the studies provided mass deworming for STH only; 
while only two studies (Adam et al., 2005; Olveda et al., 2016) provided deworming for schistosomiasis; one 
study (Elliott, Mpairwe, et al., 2005) targeted both STH and schistosomiasis. The sample size ranged from 
25 pregnant women to 22843 pregnant women. The most common co-intervention was iron/folic acid 
supplementation while other interventions included food supplementation, anti-malarial drug administration 
and education. Table 2.2 summarises deworming drugs and the co-interventions used in each study while 
table 2.3 describes the characteristics of included studies. 
 
Table 2.2: Number of studies providing each of the deworming drugs and co-interventions 









Albendazole 5 2 2 - 1 - 
Mebendazole 3 2 1 1 - 1 
Praziquantel 2 - - - - - 
Pyrantal Pamoate 1 - - - - - 
Ivermectin - 1 - - - - 
Albendazole+Praziquantel 1 - - - - - 
Ivermectin+Albendazole - 1 - - - - 
Albendazole+Mebendazole 1 - - - - - 
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Table 2.3: Characteristics of included studies 
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al., 2007; Elliott, 
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Millard et al., 2014; 
Mpairwe et al., 2011; 
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Juliet Ndibazza et al., 
2012; J Ndibazza et 
al., 2010; 
Tweyongyere et al., 
2009; Tweyongyere et 
al., 2011; 
Tweyongyere et al., 
2008; Tweyongyere et 
al., 2013; Webb et al., 
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Worm prevalence  
Mortality   
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Quality of Studies 
The quality of the included RCTs was assessed using the Cochrane risk of bias assessment criteria. Out of 
the nine RCTs included in the review; risk of bias was assessed for seven trials since and the information 
available for two trials (Tehalia, 2011; Villar et al., 1998) was not sufficient and the authors could not be 
contacted for clarification. The included RCTs were judged to be of good quality except two studies rated to 
be at high risk of attrition bias, and one study lacked allocation concealment. Figure 2.2 depicts the risk of 























Quality of non-randomised studies was assessed using the EPOC criteria. All the studies were judged to be 
at overall high risk of bias mainly due to the lack of random sequence generation and allocation concealment 
due to the design limitation. Majority of the studies were also judged to be at high risk for similarity in baseline 
outcome measurements, similarity in baseline characteristics, incomplete outcome data, lack of prevention 
of knowledge of the allocated interventions and lack of protection against contamination. Table 2.4 depicts 
the risk of bias for non-randomised studies.  




Eight studies with 8096 pregnant women; including six RCT (Deepti & Nandini, 2015; Elliott, Mpairwe, et al., 
2005; Renee Larocque et al., 2005; Ndyomugyenyi et al., 2008a; Torlesse & Hodges, 2000; Urass et al., 
2011) and two non-randomised studies (Abel et al., 2000; Christian et al., 2004) reported maternal anemia 
suggesting no important impact of mass deworming on maternal anemia in both RCTs (RR: 0.97, 95% CI: 
0.89-1.05) and non-randomised study (RR: 0.61, 95% CI: 0.14-2.76) subgroups. The outcome was judged 
to be of ‘moderate’ quality due to high risk of attrition bias in one of the studies. Figure 2.3 depicts the forest 





Figure 2.3: Forest plot for the impact of mass deworming during pregnancy on maternal anaemia 
 
Worm Prevalence 
Five studies (Elliott, Mpairwe, et al., 2005; Larocque et al., 2005; Ndyomugyenyi et al., 2008; Olveda et al., 
2016; Urassa et al., 2011) including 3307 pregnant women reported the impact of mass deworming during 
pregnancy on worm prevalence. All studies were RCTs. Mass deworming reduced the prevalence of Ascaris 
(RR: 0.24, 95% CI: 0.19-0.29), S.japonicum (RR: 0.30, 95%CI: 0.21-0.42) and S.mansoni (RR: 0.25, 95% 
CI: 0.16-0.38). There was no effect on the prevalence of hookworm (RR: 0.35, 95% CI: 0.11-1.10) and 
Trichuria (RR: 0.82, 95% CI: 0.52-1.27). The outcome was rated to be of ‘low’ quality for hookworm 
prevalence; and ‘moderate’ quality for Trichuria and Ascaris prevalence, due to high heterogeneity and high 
risk of selection bias in one of the studies. Figure 2.4 depicts the forest plot for the impact of mass deworming 









Seven studies with 5138 pregnant women; including five RCTs (Elliott, Mpairwe, et al., 2005; Ndyomugyenyi 
et al., 2008a; Olveda et al., 2016; Torlesse & Hodges, 2000; Urassa et al., 2011) and two non-randomised 
studies (Abel et al., 2000; Atukorala et al., 1994) reported maternal Hb suggesting a non-significant impact 
from RCTs (MD: 0.08 g/dL, 95% CI: -0.07-0.24), but a significant improvement in Hb from non-randomised 
studies (MD: 0.64 g/dL, 95% CI: 0.38-0.90). Figure 2.5 depicts the forest plot for the impact of mass 




Figure 2.5: Forest plot for the impact of mass deworming during pregnancy on maternal Hb 
 
Birth weight 
Five studies with 3280 pregnant women; including four RCTs (Abel et al., 2000; Elliott, Mpairwe, et al., 2005; 
Larocque et al., 2005; Ndyomugyenyi et al., 2008a; Olveda et al., 2016) and one non-randomised study 
(Christian et al., 2004) reported data on birth weight suggesting no impact from RCT (MD: 0.00 kg, 95% CI: 
-0.03-0.03) and non-randomised studies (MD: 0.05 kg, 95% CI: -0.09-0.19). Figure 2.6 depicts the forest 
plots for the impact of mass deworming during pregnancy on birth weight.  





Five studies with 8835 pregnant women; including four RCTs (Elliott, Mpairwe, et al., 2005; Larocque et al., 
2005; Ndyomugyenyi et al., 2008a; Olveda et al., 2016) and one non-randomised study (De Silva et al., 1999) 
reported data on LBW suggesting non-significant impact from RCTs (RR: 1.04, 95% CI: 0.84-1.29) while a 
significant reduction in LBW from non-randomised study (RR: 0.47, 95% CI: 0.31-0.73). The outcome was 
judged to be of ‘moderate’ quality due to high risk of selection bias in one of the studies. Figure 2.7 depicts 
the forest plot for the impact of mass deworming during pregnancy on LBW. 
Figure 2.7: Forest plot depicting the impact of mass deworming during pregnancy on LBW 
 
Preterm Birth 
Three RCTs (Larocque et al., 2005; Ndyomugyenyi et al., 2008a; Olveda et al., 2016) with 1318 pregnant 
women reported preterm birth showing a non-significant impact of mass deworming during pregnancy on 
preterm birth (RR: 0.80, 95% CI: 0.49-1.30). The outcome was judged to be of ‘moderate’ quality due to high 
risk of selection bias in one of the studies. Figure 2.8 depicts the forest plot for the impact of mass deworming 





Figure 2.8: Forest plot depicting the impact of mass deworming during pregnancy on preterm birth 
 
Perinatal Mortality 
Two RCTs (Elliott, Mpairwe, et al., 2005; Larocque et al., 2005) with 3385 pregnant women reported data on 
perinatal mortality suggesting no clear impact on perinatal mortality (RR: 1.09, 95% CI: 0.71-1.67); . Figure 
2.9. 
Figure 2.9: Forest plot for the impact of mass deworming during pregnancy on perinatal mortality 
 
Stillbirth 
Three RCTs (Elliott, Mpairwe, et al., 2005; Larocque et al., 2005; Ndyomugyenyi et al., 2008a) with 2671 
pregnant women reported data on stillbirths suggesting slight increase in stillbirth (RR: 1.83, 95% CI: 0.99-







Figure 2.10: Forest plot for the impact of mass deworming on stillbirths 
 
Neonatal Mortality 
Three RCTs (Keiser & Utzinger, 2008; J Ndibazza et al., 2010; Torlesse & Hodges, 2000) with neonates 
reported data on neonatal mortality suggesting no impact on either early (RR: 0.74, 95% CI: 0.41-1.35) or 
late neonatal mortality (RR: 0.25, 95% CI: 0.03, 2.11). Figure 2.11 depicts the forest plot for the impact of 
mass deworming during pregnancy on neonatal mortality.  
Figure 2.11: Forest plot for the impact of mass deworming during pregnancy on neonatal mortality 
 
Infant Mortality 
One non-randomised study (Christian et al., 2004) with 1147 infants reported data on infant mortality 





Five studies with 8239 pregnant women; including four RCTs (Elliott, Mpairwe, et al., 2005; Renee Larocque 
et al., 2005; Ndyomugyenyi et al., 2008; Olveda et al., 2016) and one non-randomised study (De Silva et al., 
1999) reported data suggesting no impact of mass deworming during pregnancy on congenital anomalies 
from RCTs (RR: 1.09, 95% CI: 0.79-1.49) and non-randomised study (RR: 1.26, 95% CI: 0.8-1.99). Figure 
2.12 depicts the forest plot for the impact of mass deworming on congenital anomalies. 




Summary of the Findings 
Table 2.5 reports the summary of the findings according to the GRADE criteria. Outcomes were rated to be 






Table 2.5: Summary of the findings table (RCTs only) 
Mass Deworming versus Control for STH and Schistosomiasis during Pregnancy 
Patient or population: Pregnant women in second or third trimester of pregnancy 
Settings: Antenatal clinics and community mainly in low-middle-income countries 
Intervention: Any deworming drug versus control 











Assumed risk Corresponding risk 
Control Mass deworming 
versus control 
Maternal anaemia in 
third trimester (< 11 
g/dL)  
Study population RR 0.97  






455 per 1000 395 per 1000 
(81 to 1000) 
Hookworm 
prevalence  
Study population RR 0.35 






419 per 1000 170 per 1000 
(45 to 352) 
Trichuris prevalence  Study population RR 0.82 






423 per 1000 314 per 1000  
(45 to 779) 
Ascaris prevalence  Study population RR 0.24  






300 per 1000 72 per 1000 
(0 to 170) 
LBW (birth weight < 
2500 grams) 
Study population RR 1.04 






93 per 1000 92 per 1000 
(81 to 156) 
Preterm birth (birth 
before 37 weeks of 
gestation) 
Study population RR 0.80  






39 per 1000 32 per 1000 
(10 to 83) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% 
confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the 
estimate. 
Very low quality: We are very uncertain about the estimate. 
Footnotes 
1 Downgraded by 1 for high risk of attrition bias in Torlesse 2001 and Urassa 2011. 
2 Downgraded by 2 for high risk of attrition bias in Urassa 2011 and high heterogeneity I2 = 98% 
3 Downgraded by 1 for unclear risk of selection bias in Ndyomugyenyi 2008. 
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Discussion and Conclusions  
This review summarises findings from 16 studies (31 papers) including 45,710 pregnant women. Nine of the 
included studies were RCTs while seven studies were non-randomised studies. The majority of the included 
studies targeted STH while two studies targeted schistosomiasis alone. Findings suggest that among the 
primary outcomes of the review; mass deworming during pregnancy does not have any impact on maternal 
anaemia; however mass deworming during pregnancy significantly reduced the prevalence of Ascaris, 
S.japonicum and S.mansoni. There was no impact on the prevalence of hookworm, Trichuris and any of the 
secondary outcomes including Hb, birth weight, LBW, preterm birth, perinatal mortality, stillbirths, neonatal 
mortality and congenital anomalies. The quality of the included trials was reasonable while the non-
randomised studies were judged to be of low quality. The quality of evidence according to GRADE criteria 
ranged from low to moderate. All the studies were conducted in low-middle-income countries except one 
study conducted in Hungary. Planned subgroup analysis could not be conducted due to the limited number 
of studies included in the review; however an individual participant data analysis (IPD) was planned to explore 
the findings further from this systematic review. 
These findings are consistent with the existing three systematic reviews on mass deworming during 
pregnancy (Brooker, Hotez, & Bundy, 2008; Imhoff‐Kunsch & Briggs, 2012; Salam et al., 2015). The review 
by (Brooker et al., 2008) only included hookworm studies suggesting that there is insufficient data to quantify 
the benefits of deworming. This review however also recommended increased coverage of anthelminthic 
treatment among pregnant women. The review by (Imhoff‐Kunsch & Briggs, 2012) evaluated deworming for 
STH and concluded that there was no clear benefit of deworming on maternal, newborn and child health 
outcomes, however the review suggested that there may be a public health benefit to alleviate the burden of 
STH infections in pregnant women. Finally, the Cochrane review by (Salam et al., 2015) evaluating 
deworming for STH concluded that the evidence was insufficient to recommend use of deworming drugs for 
STH among pregnant women. This review focused on RCTs only and did not measure worm prevalence as 
an outcome. Our systematic review collates the most recent evidence on mass deworming for STH and 
schistosomiasis during pregnancy suggesting that the intervention is effective in reducing the worm burden; 
however there is little impact on any other maternal, birth or newborn health outcomes.   
Despite of the comprehensive evaluation of the effectiveness of mass deworming during pregnancy for STH 
and schistosomiasis in this review; there are some limitations and questions that remain beyond the scope 
of this exercise and still remain unanswered. Firstly, the number of trials included in the existing evidence 
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base is very small; that is only seven trials; of which only one trial assessed the effectiveness of mass 
deworming for schistosomiasis. Secondly, the analysis is limited in scope to make inferences for concurrent 
administration of iron supplementation, variable periods of follow-up, different baseline prevalence (and 
intensities) of infections; owing to the small sample size. Thirdly, all the included studies provided preventive 
mass deworming (deworming drugs administered to the entire population disregarding their infection status 
with the intent of providing treatment benefit to those who are infected and uninfected persons are treated 
because the program is applied to the whole population for logistical and cost reasons); and hence measuring 
the benefits of the intervention on the entire treated group therefore might not be appropriate as benefits 
might only accrue to those infected and not to those uninfected. Fourthly, the prevalence and intensity of 
STH and schistosomiasis infections varied greatly across the included studies. Finally, other interventions 
(including water, sanitation and hygiene interventions) also need to be evaluated along with deworming for 
the control of morbidity. There is a need to critically appraise the existing studies in order to account for 
various factors that could modify the effectiveness of mass deworming including nutritional status, type of 
infection, worm burden and other concomitant interventions (Barry et al., 2013; Turner et al., 2015). Since 
systematic reviews are conducted at the study level, rather than using data for each individual participant, 
the power of the systematic reviews to detect effect modification by individual participant characteristics is 
limited. Currently, it is difficult to establish whether deworming during pregnancy has beneficial effects under 
certain conditions and limited effects under others and there exists a possibility that it is only beneficial in 
women with very high parasite burdens, dietary insufficiencies, or both (Blackwell, 2016). An IPD meta-
analysis was planned to explore the question of whether mass deworming during pregnancy is more effective 
for subgroups of women defined by characteristics such as nutrition status and infection intensity. Findings 









Chapter 3: Systematic review and meta-analysis to assess the 
effectiveness of interventions other than deworming for pregnant women 




Mass deworming with anthelminthic drugs is endorsed as an effective strategy for the prevention and control 
of soil transmitted helminthiases (STH) and schistosomiasis. However, deworming alone offers only a short 
term control unless augmented by additional control interventions (including water, sanitation and hygiene 
interventions) to break the infection transmission cycle. Furthermore, there are concerns related to drug 
resistance associated with the scale-up of periodic mass deworming campaigns. 
Methods 
We conducted a systematic review and meta-analysis to assess the effectiveness of interventions other than 
deworming (based on our conceptual framework) for pregnant women and women of reproductive age (WRA) 
on maternal, birth and newborn health outcomes. We used a comprehensive search strategy to identify 
eligible studies regardless of date of publication, language, or publication status till March 2018.  
Findings  
From a total of 2324 records identified; seven studies fulfilled the eligibility criteria and were included in this 
review. One study was a quasi-experimental study; one prospective cohort study; while five studies were 
cross-sectional. Two studies included pregnant women while all other studies included WRA. Studies were 
conducted in Bangladesh, China, Kenya, Rwanda, Tanzania and Vietnam. None of the included studies 
reported any of the pre-defined primary or secondary outcomes and meta-analysis could not be conducted 
due to the study design limitations and heterogeneity in the studies. Findings from one quasi-experimental 
study suggested that health education related to schistosomiasis prevention and treatment was significantly 
associated with reductions in the rate of infested water exposure and infection rate. Data from other included 
cross-sectional studies suggested that STH and schistosomiasis prevalence is significantly associated with 
geophagy during pregnancy, hand washing, consuming piped water and availability of latrine.  
Interpretation 
This review suggests that the existing evidence pertaining to interventions other than deworming among 




Recent data from the Global Burden of Diseases (GBD) Study suggests that soil transmitted helminthiasis 
(STH) infections (including ascariasis, trichuriasis, and hookworm infections) accounted for 1.75 billion 
prevalent cases; while schistosomiasis alone accounted for 291 million prevalent cases in 2013 (Herricks et 
al., 2017). Ascariasis, trichuriasis, and hookworm infections alone are accountable for more than three-
quarters of the total prevalence of neglected tropical diseases (NTD). Moreover, over the last two decades, 
there has been no substantial reduction in the prevalence of schistosomiasis and only a modest impact on 
hookworm and trichuriasis has been observed (Herricks et al., 2017). Among adolescent and adult women, 
schistosomiasis and hookworm infection still remain the leading causes of disability adjusted life years 
(DALYs) (Kassebaum et al., 2014). Furthermore, DALYs for schistosomiasis may have been even higher if 
female genital schistosomiasis is taken into consideration (Herricks et al., 2017).  
STH is transmitted through the eggs present in the faeces of an infected person which contaminate the soil 
in areas with poor water and sanitation facilities. These eggs mature in soil and infect other people when 
ingested through contaminated hands or food or penetrate the skin of the person walking barefoot on 
contaminated soil. Schistosomiasis is transmitted when infected persons’ faeces containing parasite eggs 
are released in fresh water, these eggs hatch and the subsequent larvae infect susceptible snail hosts. These 
larvae undergo asexual multiplication in snails and release another larval stage into water which penetrate 
the skin during contact with infested water and infect the human host during domestic, occupational and 
recreational contact with water. Figure 3.1 depicts the transmission cycle for STH. 




Currently, no vaccines are licensed for STH and schistosomiasis; and mass deworming with anthelminthic 
drugs is endorsed as an effective strategy for the prevention and control along with appropriate water, 
sanitation and hygiene (WASH) interventions and education (WHO, 1994, 2017). Deworming treatment alone 
offers only a short term control unless augmented by additional control interventions to break the transmission 
cycle. Deworming drugs kill the adult parasites within the human host but do not prevent rapid reinfection if 
the host contacts an environment contaminated with infective stages of the parasites. Therefore, there exists 
a risk that the prevalence of infection will return to pre-treatment levels within six to 12 months of a single 
round of deworming (Campbell, Savage, & Gray, 2014; Freeman et al., 2013; Jia, Melville, Utzinger, King, & 
Zhou, 2012). Furthermore, there are concerns related to drug resistance associated with the scale-up of 
periodic mass deworming campaigns (Moser et al., 2017; Palmeirim et al., 2018).  
A massive burden of disease is associated with insufficient hygiene, sanitation, and water supply and this is 
largely preventable with proven, cost-effective interventions (Bartram & Cairncross, 2010). Inadequate 
WASH is estimated to be responsible for 4% of deaths and 5.7% of disease burden worldwide, primarily 
driven by its role in the transmission of diarrhoeal disease and helminthiases (Prüss, Kay, Fewtrell, & Bartram, 
2002). Geographically, the prevalence of the STH and schistosomiasis is especially high in the large middle-
income countries in Oceania, Southeast Asia, and South Asia; countries where WASH facilities are highly 
inadequate (Herricks et al., 2017; WHO). The WHO identifies girls and women of reproductive age (WRA) 
amongst the most vulnerable population groups for STH and schistosomiasis (WHO, 2006); however these 
groups remains the most neglected groups for WASH facilities especially in poor resource settings (Giné-
Garriga, Flores-Baquero, de Palencia, & Pérez-Foguet, 2017). A recent feasibility modelling study suggested 
that it is possible to stop STH transmission; however it will require a collaborative approach including a clean 
environment, appropriate delivery platforms and strong political will (Brooker et al., 2015).  
The existing data evaluating the impact of WASH interventions on STH schistosomiasis is scarce; of low 
quality; and on general population groups rather than the population groups vulnerable to the disease (Grimes 
et al., 2014; Salam et al., 2014; Strunz et al., 2014; Ziegelbauer et al., 2012). Furthermore, the existing 
reviews fail to assess the impact of WASH interventions during pregnancy in addition to mass deworming 
and its impact on maternal, newborn and health outcomes. The aim of this review, therefore is to assess the 
effectiveness of interventions other than deworming (including WASH interventions) on maternal, birth and 




To evaluate the effectiveness of interventions other than deworming (including WASH interventions) for WRA 
on maternal, birth and newborn health outcomes.  
Methodology 
Criteria for considering studies for this review 
Types of studies 
We included primary studies using experimental or quasi-experimental study designs that allow for causal 
inferences. We aimed to include randomised controlled trials (RCTs), quasi randomised studies and 
controlled before after studies (CBA); however we did not find any eligible RCTs. We also included case-
control and cross-sectional studies reporting associations between WASH interventions and maternal, birth 
and newborn health outcomes. We excluded case reports and case-series.  
Types of participants 
Participants were WRA receiving interventions other than deworming (including WASH interventions and 
education) for STH and schistosomiasis prevention and management. For the studies including WRA as a 
subset of the total study population, we only included such studies if the results were separately provided for 
the WRA subgroup.  
Types of interventions 
We included any intervention other than deworming compared to no intervention. Interventions could include 
WASH interventions like use of latrines, sewage disposal, safe water, wearing shoes, hand washing before 
eating and after defecation, nutrition and food safety, and education. We excluded studies that only reported 
associations between participant knowledge of the WASH strategies and outcomes of interest. Studies 
assessing the efficacy of different methods to assess exposures to risk factors were also excluded.     
Types of outcome measures 
The following primary and secondary outcomes were reported. However we did not use the list of outcomes 
as a criterion for inclusion, that is, we included studies if they fulfilled the eligibility criteria and did not report 
any of the following outcomes of interest.  
-Primary outcomes: 
 Maternal anaemia at term (defined as haemoglobin (Hb) less than 11 g/dL) 
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 Maternal infection intensity (as defined and reported by the study authors) 
-Secondary outcomes: 
 Maternal Hb at term  
 Maternal ferritin at term 
 Maternal anthropometric measures (including maternal weight, body mass index (BMI), gestational 
weight gain etc.)  
 Birth weight 
 Low birth weight (LBW) (defined as birth weight less than 2500 grams)  
 Preterm birth (defined as birth before 37 weeks of gestation)  
 Perinatal mortality (includes foetal death after 28 weeks of gestation and neonatal death that occurs 
at less than seven days of life)  
 Stillbirth (defined as a baby born with no signs of life at or after 28 weeks' gestation) 
 Congenital anomalies (defined as structural or functional anomalies (e.g. metabolic disorders) that 
occur during intrauterine life and can be identified prenatally, at birth or later in life) 
 Infant mortality (defined as the number of deaths among children under one year of age occurring 
among the live births in a given geographical area during a given year, per 1,000 live births occurring 
among the population of the given geographical area during the same year) 
Search methods for identification of studies 
We used a comprehensive search strategy to identify eligible studies regardless of date of publication, 
language, or publication status till March 2018. The search strategy is attached as Appendix 3. 
Electronic searches  
We searched the following electronic databases: MEDLINE, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Latin-American and Caribbean System on Health Sciences Information (LILACS), 
Excerpta Medica dataBASE (EMBASE), the Cochrane Library, Global Health CABI and Centre for Agriculture 
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and Biosciences (CAB) Abstracts. We searched websites of relevant organizations such as the WHO 
Neglected Tropical Diseases, World Bank and World Food Program.  
Searching other resources 
We also contacted authors of studies and members of the study’s advisory board for any unpublished studies 
or grey literature reporting eligible studies. We checked reference lists of relevant studies and reviews. We 
also searched for trials registered with ClinicalTrials.gov. 
Data collection and analysis  
Selection of studies  
Two reviewers independently assessed potential study eligibility using predefined screening criteria. Any 
studies considered obviously irrelevant from screening the titles and/or abstracts were excluded at the first 
level. Any uncertainties at the first level screening were re-assessed on the basis of full text in the second 
level of screening. For any discrepancies, study’s advisory group was contacted for the final decision. Any 
disagreements were resolved through discussion until a consensus was reached.  
Data extraction and management  
We extracted data from included studies on the following: 
 Background: time period when study took place, type of publication (e.g. full-text journal article, 
abstract, conference paper, thesis) and study country or countries. 
 Population and study setting: population age and setting. 
 Methods: study design, description of study arms, unit of allocation, sample or cluster size per study 
arm (for individually or cluster randomised trials respectively), start and end date, duration of follow 
up. 
 Participants: total number randomised, baseline characteristics, number of withdrawals, socio-
demographic data (if available).  
 Intervention group details: number randomised to group, description of intervention, co-interventions, 
duration and follow-up, timing and delivery of intervention. In case of studies with multiple intervention 
arms, we described all arms, while we reported the arms that met the inclusion criteria. 
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 Comparison group details: number randomised to group, description of comparison, duration and 
follow-up, timing and delivery. 
 Outcomes: measurement tool, total number in intervention and comparison groups, change indicated 
at each time point. In case if multiple measures are reported for the same outcome construct, we 
used the one pre-specified in protocol. 
 Any other information deemed relevant.  
Assessment of risk of bias in included studies  
We assessed the quality of the included studies using the Cochrane risk of bias assessment tool for the 
RCTs. The quality of the RCTs was assessed based on selection bias, performance bias, detection bias, 
attrition bias and reporting bias (Higgins et al., 2011).  For non-randomised studies, we used the Cochrane 
Effective Practice and Organisation of Care (EPOC) group criteria for risk of bias assessment (EPOC, 2015). 
Quality of non-randomised studies was assessed based on baseline outcome measurements similar, 
baseline characteristics similar, incomplete outcome data, knowledge of the allocated interventions 
adequately prevented during the study, protection against contamination, selective outcome reporting and 
other risk of bias. We summarised the quality of evidence according to the outcomes as per the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) criteria (Guyatt et al., 2011). A grade 
of “high”, “moderate”, “low” and “very low” were used for grading the overall evidence indicating the degree 
of certainty of an effect on specific health outcome based on methodological flaws within the component 
studies, consistency of results across different studies, generalizability of research results to the wider patient 
base and how effective the treatments have been shown to be (Balshem et al., 2011).  
Measures of treatment effect  
For each outcome, data were converted to the same format (e.g. means and standard deviations for 
continuous data), including appropriate conversion of scales such that an increase/decrease always indicates 
improvement or deterioration of an indicator. Dichotomous and continuous outcomes were analysed 
separately. For dichotomous outcomes, results were presented as summary risk ratios (RRs) or odds ratio 
(OR) with 95% confidence intervals (CI), whenever possible, in order to compare risk of the outcome between 
intervention and control groups. Continuous outcome data were presented as either a mean difference (MD), 
if outcomes were measured on the same scale, or a standardized mean difference (SMD), if outcomes were 
measured on different scales, with 95% CI.  
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Unit of analysis issues  
In order to take into account potential sources of dependency, we grouped studies in terms of their location, 
population and the intervention being evaluated to ensure that there was no double counting of evidence 
when synthesizing results across studies. If there were multiple papers that described the same study, these 
were combined and coded as a single study. 
For studies that included multiple intervention arms, we planned to select one pair (intervention and control) 
that satisfied the inclusion criteria of the review and exclude the rest. If more than two intervention groups 
met the eligibility criteria, then we planned to combine these groups into a single pair-wise comparison group 
and combined data were disaggregated into corresponding subgroups, or these arms were separated into 
different forest plots to ensure that there is no double counting of participants. However, we did not come 
across any such study.  
Dealing with missing data  
Where data were incomplete or in a form that could not be converted with the information available, we 
contacted the corresponding author for clarification or to obtain missing data. If authors accounted for missing 
data (i.e. multiple imputations), we used the adjusted data within our analysis. 
Assessment of heterogeneity  
Clinical and methodological heterogeneity was explored by assessing the similarities and differences in 
included studies' participants, interventions, outcomes, and methods. Statistical heterogeneity was assessed 
by visually inspecting forest plots, calculating the I2 statistic (>50% indicated substantial heterogeneity) and 
conducting a Chi2 test, where a p-value <0.1 was considered statistically significant. Sources of heterogeneity 
was explored using sub-group analysis (where possible). 
Assessment of reporting bias  
If the number of studies was sufficient (>10), funnel plots were used to visually assess publication bias. This 
kind of bias is unlikely if data forms a symmetric inverted funnel shape around the mean effect estimate.  
Data synthesis  
We planned to conduct meta-analysis using Review Manager 5.3, for comparable interventions and 
outcomes. However, due to limitation in the study design and heterogeneity in the included studies, we could 
not conduct meta-analysis for this review and have reported the findings narratively. For interpretation of 
results, overall effect estimates that had an associated p-value <0.05 were deemed statistically significant. 
Non-significant findings were also reported.  
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Subgroup analysis and investigation of heterogeneity  
Depending on data availability, we planned an exploratory sub-group analyses on the primary outcomes for 
the various types of interventions; however due to limited number of studies included in this review, we could 
not conduct any subgroup analysis. 
Sensitivity analyses  
Sensitivity analyses was planned to be conducted to determine whether the removal of studies with high risk 
of bias or the removal of non-randomised studies significantly impact findings. However, we could not conduct 
any sensitivity analysis due to the limited number of studies included in this review. 
Results 
Search results 
A total of 2324 records were identified using the search strategy specified in Appendix 3. Seven papers 
fulfilled the eligibility criteria and were included in the review. Majority of the studies were excluded since they 
did not provide data on WRA. Figure 3.2 depicts the search flow diagram and Appendix 4 provides reasons 
for exclusion for the excluded studies. 
Figure 3.2: Search Flow Diagram 
 
Characteristics of studies 
A total of seven studies were included: one quasi-experimental study (Guanghan et al., 2000); one 
prospective cohort study (Luoba et al., 2005); and five cross-sectional surveys (Benjamin-Chung et al., 2015; 
Ivan et al., 2013; Nguyen, Nguyen, Nguyen, & Le, 2006; Sera et al., 2007; Stothard et al., 2008). Two studies 
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(Ivan et al., 2013; Luoba et al., 2005) included pregnant women while all others included WRA. Studies were 
conducted in Bangladesh, China, Kenya, Rwanda, Tanzania and Vietnam. None of the included studies 
reported the pre-defined primary or secondary outcomes. We could not conduct meta-analysis due to the 
study design limitations and heterogeneity in the studies and hence the findings were narratively summarised. 
Characteristics of the included studies are summarised in table 3.1. 
Findings    
One quasi-experimental study (Guanghan et al., 2000) assessed the impact of health education for 
schistosomiasis control in a heavily endemic area of Poyang Lake region in China. The study included 559 
participants including children and adults; findings were reported separately for children, adult women and 
men. Health education was implemented in the experimental group and the results were compared to a 
control area without health education. Health education comprised of anti-schistosomiasis knowledge, 
showing video tapes about schistosomiasis control, exhibiting the samples of Schistosomiasis japonica and 
pasting up pictures about schistosomiasis control. Training on techniques for preventing infection with S. 
japonicum and how to wear appliances and smear medicine for protection was also provided. Findings from 
this study suggests that health education for schistosomiasis prevention and management led to increased 
anti-schistosomiasis knowledge among WRA along with reduction in the rate of infested water exposure 
(6.7% in the intervention group compared to 11.5% in the control group) and infection rate (7.1% in the 
intervention group compared to 21.1% in the control group). The study concluded that health education 
regarding schistosomiasis prevention is potentially effective in reducing infection S. japonicum among WRA. 
Two studies; one prospective cohort and one cross-sectional survey, assessed the association between 
geophagy and reinfection with STH among pregnant women and WRA. The prospective cohort study was 
conducted among 827 pregnant women in Nyanza Province in western Kenya (Luoba et al., 2005). This 
study assessed the effect of earth-eating (geophagy) during pregnancy on STH reinfection after treatment. 
The women were recruited at a gestational age of 14 to 24 weeks and followed up to 6 months postpartum. 
After deworming of the infected women with mebendazole (500 mg, single dose) at 32 weeks gestation, the 
women were reassessed for infection post-partum. The re-infection rate for hookworm was found to be 
14.8%, for T. trichiura 6.6%, and for A. lumbricoides 5.2% at three months postpartum, and 16%, 5.9% and 
9.4% at six months postpartum. The study concluded that geophagy is associated with re-infection with STH 
among pregnant and lactating women and that intensities built up more rapidly among geophagous women. 
Another cross-sectional survey was conducted among 970 women from Pemba Island, Zanzibar, Tanzania 
that assessed association between geophagy and STH prevalence (Sera et al., 2007). This study suggested 
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that neither the prevalence nor the intensity of infection with Ascaris, Trichuris or hookworm differed 
significantly by geophagy status.  
Four studies were cross-sectional surveys. One cross-sectional study was conducted among 980 HIV-
infected pregnant females from health centers in rural and peri-urban locations in the central and eastern 
provinces of Rwanda (Ivan et al., 2013). The prevalence of any STH infections was found to be 34.3% among 
pregnant women. Findings suggest that hand washing was associated with reduced infection with any STH 
(OR:  0.29, 95% CI: 0.19 to 0.46) as well as with infections with Trichuris (OR: 0.52, 95% CI: 0.33 to 0.8) and 
hookworm (OR: 0.2, 95% CI: 0.1 to 0.4). Consuming piped water compared to river water was associated 
with significant reductions in Ascaris prevalence (OR: 0.30, 95% CI: 0.16 to 0.53); as well as any STH 
infection (OR: 0.23, 95% CI: 0.14 to 0.38).  Findings from this study suggest that HIV-positive pregnant 
women would benefit from the scaling up of de-worming programs alongside health education and hygiene 
interventions.  
Another cross-sectional survey in 100 villages in rural Bangladesh assessed exposures to self-reported 
deworming consumption in the past six months, access to a hygienic latrine, and household flooring material 
among 532 WRA (Benjamin-Chung et al., 2015). The prevalence of any infection among WRA in this study 
was 30.3%, prevalence of Ascaris was 11.8%, prevalence of hookworm was 6.4% and prevalence of Trichuris 
was 18.2%. Another study utilized the nationwide survey data from Vietnam to assess the risk factors for 
STH infection among 5127 women (Nguyen et al., 2006). About 76% women were found to be infected with 
one or more STH species; 36% with hookworm, 59% with Ascaris lumbricoides and 28% with Trichuris 
trichiura. Hookworm infection was found to be associated with a lack of a closed latrine (OR: 2.1; 95% CI: 
1.4 to 3.1). This study concluded that WRA, especially rural farmers, should be included among the high 
priority groups for STH control programs through mass deworming and improving sanitation. Another cross-
sectional study conducted across 10 Ungujan villages in Zanzibar among 322 mothers and their pre-school 
children suggested that among mothers, the mean prevalence for ascariasis was found to be 6.7%, for 
trichuriasis was 11.9% and for hookworm was 1.9% (Stothard et al., 2008). Findings from this study 
suggested that access to a household latrine was a significantly associated protective factor for any STH 
infection (OR: 0.56; 95% CI: 0.32 to 0.99). The study concluded that intervention efforts should be stepped 
up and greater efforts placed upon improving household sanitation. 
Table 3.2 summarizes the associations between various WASH exposures and worm burden from the 
included studies.  
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Table 3.1: Characteristics of the included studies 
Serial 
No 
Study ID Study 
Design 


















Exposure to: self-reported deworming 
consumption in the past six months, access 
to a hygienic latrine, and household flooring 
material 
 Prevalence of STH 











area of Poyang 
Lake including two 
natural villages, 
Lotun and Taojia, 
located in Xinjian 
county of Jiangxi 
Province, were 
selected as field 





Health education for schistosomiasis control 
including education based on anti-
schistosomiasis knowledge by showing 
video-tape about schistosomiasis control, 
exhibiting the samples of schistosomiasis 
japonica and pasting up the pictures about 
schistosomiasis control and lecturing the 
technique of protecting from infection with 
S.japonicum and setting an example for how 
to wear appliances and smear medicine for 
protecting from infection with S.japonicum. 
A single course of anti-schistosomiasis was 













3. Ivan 2013 





Health centres in 
rural and peri-
urban locations in 








Exposure to: education, employment, hand 
washing, piped/river water, wearing shoes 
and dietary supplements   
 Prevalence of 





malaria co-infection  
Association of 
helminthic infection 
with water, shoe 
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wearing and hand 
washing   
4. Luoba 2005 











Exposure to geophagy-earth-eating habit  Prevalence of 











Vietnam  5127 non-
pregnant 
women  
Exposure to geographic area, occupation, 
education and place of defecation 


























Exposure to knowledge about STH, 
household latrine, access to local health 
services, received STH treatment ever, 
received Vitamin A supplement ever, child 
immunizations, wear shoes/sandals, play on 
the ground, have ever passed blood in stool, 
have ever passed worms in stool 




7. Sera 2007 











Exposure to geophagy during current 
pregnancy, age, urban or rural residence, 
ownership by household of four durable 
goods (bicycle, radio, home lit by electric 
and/or glass lanterns and a metal roof), 
presence of pit toilet in the home and 
whether the woman had received formal 
education 











Table 3.2: Associations between WASH exposures and worm burden 
Study Worm 
Species 
Prevalence by Exposure 
Prevalence Ratio (PR) or Odds Ratio (OR) or Percentage Prevalence (PP) with 95% CI 
  Access to Hygienic 
Latrine 





Chung et al., 
2015) 
Ascaris PR: 0.91 (0.67, 1.24) PR: 0.56 (0.32, 0.97)     
 Hookworm PR: 0.73 (0.43, 1.24) PR: 0.48 (0.16, 1.45)     
 Trichuris PR: 1.03 (0.84, 1.27) PR: 0.98 (0.72, 1.33)     
Ivan 2013 
(Ivan et al., 
2013) 
Ascaris   OR: 0.30 (0.16, 0.53) OR: 0.52 (0.33, 0.80)   
 Hookworm Not Reported 
 Trichuris    OR: 0.20 (0.10, 0.40)   
Luoba 2005 
(Luoba et al., 
2005) 
Ascaris     PP: 6.0 (4.0, 9.0)  
 Hookworm     PP: 9.6 (5.3, 
13.9) 
 
 Trichuris     PP: 3.4 (1.2, 5.6)  
Nguyen 2006 
(Nguyen et al., 
2006) 
Ascaris NR      
 Hookworm      2.1 (1.4, 3.1) 
 Trichuris       
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Discussion and Conclusions  
This review summarizes findings from seven studies with 8962 participants. Except for one quasi-
experimental study and one prospective cohort all other studies were cross-sectional surveys. We could not 
conduct meta-analysis due to the study design limitations and heterogeneity between the included studies. 
Results from the included studies were summarized narratively. Findings from one quasi-experimental study 
suggested that health education related to schistosomiasis prevention and treatment was significantly 
associated with reductions in the rate of infested water exposure and infection rate. Data from other cross-
sectional studies suggested that STH and schistosomiasis prevalence was significantly associated with hand 
washing, consuming piped water and availability of latrines. This review suggests that despite the proven 
role of water, sanitation and hygiene measures in prevention of STH and schistosomiasis, the existing 
evidence is scarce and of low quality. This systematic review has some limitations: firstly only one study 
assessed causal inference between intervention and outcome since all other studies were cross-sectional 
surveys. There are many factors that could confound the relationship between WASH access or practices 
and STH and schistosomiasis prevalence, including socioeconomic status, age, gender and mass deworming 
programs in the study region that were not accounted for in the included studies. Secondly, meta-analysis 
could not be conducted due to limited number of studies and study design limitations. 
These findings are consistent with the existing systematic reviews in wider population groups (Grimes et al., 
2014; Strunz et al., 2014; Ziegelbauer et al., 2012) suggesting that availability of sanitation, use of sanitation, 
use of treated water, access to piped water, wearing shoes, hand washing (both before eating and after 
defaecating) and soap use or even availability is significantly associated with reduced STH and 
schistosomiasis prevalence. Community based packaged delivery of interventions including health education 
to promote general hygiene and sanitation along with drug administration, iron and β-carotene 
supplementation, snail control, constructing latrines, eliminating cattle from the residential areas, staff 
training, and community mobilization have also been found to be associated with reduced prevalence of STH 
and schistosomiasis, improved mean haemoglobin and reduced anaemia prevalence with no clear impact on 
ferritin, height, weight, LBW or stillbirth (Salam et al., 2014). However, the existing reviews have assessed 
these interventions in general population groups and not specifically among pregnant women or WRA.  
Improvements of WASH infrastructure and appropriate health-seeking behavior are necessary for achieving 
sustained control, elimination, or eradication of STH and schistosomiasis. A recent feasibility modelling study 
suggested that a collaborative approach including clean environment, appropriate delivery platform and 
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strong political will have the potential to break the STH transmission cycle (S. J. Brooker et al., 2015). 
Moreover, in order to improve drug compliance for schistosomiasis there is an urgent need for intensive 
health education campaigns before conducting mass drug administration (MDA) in order to provide disease 
specific information and counter the prevailing misconceptions about transmission, prevention, treatment, 
and drug side-effects (Inobaya et al., 2018). Despite this acknowledgement, very few programs to control 
STH and schistosomiasis have specific WASH focused-interventions, targets and approaches and the 
number further dwindles when it comes to targeting WRA and pregnant women. WHO has recently published 
a new Global Strategy: ‘Water, Sanitation and Hygiene for accelerating and sustaining progress on Neglected 
Tropical Diseases’ focusing on cross-cutting actions that benefit disease control for NTDs and strengthen 
health systems (Boisson et al., 2016). Increased attention towards WASH for STH and schistosomiasis has 
a great potential to catalyze synergies with integrated NTD control programs, while jointly elevating 
awareness of WASH and NTDs. Additional high-quality implementation research is needed to explore the 
potential of integrated WASH interventions alongside mass deworming programs.  
Research Priorities 
Following are the key research priorities when considering WASH intervention for reducing the burden of 
STH and schistosomiasis along with deworming: 
-To understand the relative importance of STH and schistosomiasis transmission and implications for 
effective WASH interventions. 
-To assess the access and coverage of WASH interventions among vulnerable population groups followed 
by rigorously evaluating the effectiveness of conventional WASH interventions on transmission. 
-To evaluate the relative effectiveness of combined WASH and deworming versus deworming alone on 
transmission in different settings and for different populations. 
-To evaluate whether WASH interventions can improve maternal and neonatal health outcomes in context of 
STH and schistosomiasis. 
-To design and evaluate behavior change interventions to increase WASH uptake. 
-To design and evaluate behavior change interventions that improve the sustainability of other hygiene 
behaviors (e.g. personal and domestic hygiene) in endemic populations. 
72 
 
Chapter 4: An individual participant data (IPD) meta-analysis to identify 




Mass deworming is recommended as an effective strategy to prevent and treat soil-transmitted helminthiases 
(STH) and schistosomiasis. However there is a great deal of heterogeneity in the existing evidence and the 
effectiveness of mass deworming in improving various maternal and newborn health outcomes is a current 
source of debate. Critical appraisal of existing studies suggests that these studies fail to account for various 
factors that could modify the effectiveness of deworming including nutritional status, type of infection, worm 
burden and concomitant interventions. Currently, it is difficult to establish whether mass deworming during 
pregnancy has beneficial effects under certain conditions and limited effects under others. 
Objective 
The objective of the review is to use individual participant data (IPD) meta-analysis to explore whether the 
effect of mass deworming during pregnancy varies with individual characteristics (nutritional status, 
anaemia), intensity of infection (as assessed by egg count), infection status (including species of worm), 
socioeconomic status, sanitation environment and co-interventions. 
Search methods 
We developed a search strategy with an information scientist to search MEDLINE, Cumulative Index to 
Nursing and Allied Health Literature (CINAHL), Latin-American and Caribbean System on Health Sciences 
Information (LILACS), Excerpta Medica dataBASE (EMBASE), the Cochrane Library, Internet Documents in 
Economics Access Service (IDEAS), Google Scholar, Web of Sciences, Social Services Abstracts, the World 
Health Organization (WHO) Global Health Library, Global Health CABI and CAB Abstracts till March 2018. 
We also searched grey literature, websites, contacted authors and screened references of relevant 
systematic reviews. 
Selection criteria 
We included individually randomised controlled trials; cluster randomised controlled trials and quasi-




Data collection and analysis 
We contacted all eligible study authors to invite them to join our investigators’ collaborative group and share 
their individual participant data.  We used a data sharing agreement. All IPD were assessed for 
completeness, compared to published reports and entered into a common data spreadsheet. Risk of bias 
was assessed using the Cochrane Risk of Bias tool.  Overall quality of the evidence was assessed using the 
Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methods. This review 
was registered as a protocol in the Campbell Collaboration Library. 
Results 
We screened 23,406 records and identified a total of 16 studies on mass deworming during pregnancy; out 
of which seven trials with 8515 participants were deemed to be eligible for IPD. Trial authors were contacted 
for all seven trials deemed eligible for the IPD. Out of the seven trials, we received data from three trials; data 
from two trials were no longer available (trialists were not able to retrieve the data); one trialist refused to 
share the data while one could not be contacted due to severe health conditions. This IPD analyzed the 
majority of the existing data; out of 8515 potential IPD participants; data were captured for 5957 (70%) 
participants.  
Findings from this IPD suggest that mass deworming during pregnancy reduces maternal anaemia by 23% 
(risk ratio (RR): 0.77, 95% confidence interval (CI): 0.73-0.81; three trials; 5216 participants; moderate quality 
evidence). Mass deworming during pregnancy did not have any impact on any of other outcomes including 
Trichiura infection (RR: 0.69, 95% CI: 0.42-1.13; two trials; 2867 participants; moderate quality evidence), 
hookworm infection (RR: 0.52, 95% CI: 0.18-1.47; two trials; 2867 participants; moderate quality evidence), 
low birth weight (LBW) (RR: 0.89, 95% CI: 0.67-1.18; two trials; 2267 participants; moderate quality evidence) 
and preterm birth (RR: 0.69, 95% CI: 0.47-1.03; two trials; 2707 participants; moderate quality evidence). 
Due to limited availability of the data on the pre-defined effect modifiers, we could only assess for effect 
modification by baseline Trichiura infection, maternal anaemia at baseline and maternal body mass index 
(BMI) at baseline. There was no evidence of effect modification by Trichiura intensity at baseline, maternal 
anemia at baseline and maternal BMI at baseline. However these findings should be interpreted with caution 
due to small sample sizes. 
The quality of evidence is rated as moderate for our findings. Further studies accounting for maternal baseline 
worm intensities, concomitant iron/folic acid supplementation and antenatal care coverage could change our 




Our analyses suggest that mass deworming during pregnancy is associated with reducing anaemia with no 
apparent impact on any other maternal or pregnancy outcomes. Our analyses were limited by the availability 
of data for the impact by subgroups and effect modification and thus there is a need to assess mass 
deworming for STH and schistosomiasis during pregnancy in large scale programmatic settings along with 
an attempt to measure various individual and environmental factors that could potentially affect its impact. 




















The World Health Organization (WHO) identifies three population groups at high risk for soil transmitted 
helminthiases (STH) and schistosomiasis including school-age children, preschool children, and girls and 
women of reproductive age (WRA) (WHO, 2006). A recent estimation suggests that approximately 688 million 
girls and WRA are at risk of STH infection; including 140 million pregnant and lactating women and another 
108 million adolescent girls (Mupfasoni et al., 2018). Approximately 40 million WRA are infected with 
schistosomiasis (Friedman et al., 2007; Nour, 2010). Geographically, the WHO South-East Asia and African 
regions have the highest numbers of WRA subgroups, accounting for 74.7% of all STH at-risk WRA 
(Mupfasoni et al., 2018). STH and schistosomiasis during pregnancy causes active and debilitating disease 
with adverse effects on birth outcomes and the infant’s developing immune system (Bustinduy et al., 2017; 
Freer et al., 2017; Sanya et al., 2017).  
The WHO recommends mass deworming for STH and schistosomiasis depending on prevalence of worm 
infection. Preventive chemotherapy (deworming), using single-dose albendazole (400 mg) or mebendazole 
(500 mg), is recommended as a public health intervention for pregnant women. For schistosomiasis, annual 
treatment with praziquantel in high risk communities (>50%) and once every two years in medium risk 
communities (>10% and <50%) is recommended and women can be treated with praziquantel at any stage 
of pregnancy and lactation. In addition to deworming; education on health and hygiene and provision of 
adequate sanitation is also recommended.  
Mass drug administration (MDA) along with the water, sanitation and hygiene (WASH) interventions are 
generally accepted as effective measures to prevent and treat STH and schistosomiasis. However, findings 
from existing studies are conflicting and the effectiveness of MDA in improving various maternal and child 
health outcomes is a current source of debate (Turner et al., 2015). Findings from the systematic review 
detailed in Chapter 2 suggests that mass deworming during pregnancy is associated with reducing worm 
burden with no impact on any other maternal or pregnancy outcomes including anaemia, haemoglobin (Hb), 
birth weight, low birth weight (LBW), preterm birth, perinatal mortality, stillbirths, neonatal mortality and 
congenital abnormalities. An existing Cochrane review of deworming using anthelminthics in the second 
trimester of pregnancy including four trials and 4265 participants concluded that there was insufficient 
evidence to recommend mass deworming in pregnancy (Salam et al., 2015).  There was no impact of a single 
dose of anthelminthic in the second trimester of pregnancy on maternal anaemia in the third trimester, LBW, 
preterm birth and perinatal mortality. This review did not assess the impact of deworming on worm burden 
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and intensity. A recent Campbell systematic review and network meta-analysis with 47 randomised trials and 
over one million children, found little to no overall effect on growth, attention and school attendance (Welch 
et al., 2016). However, these reviews were conducted at the study level, rather than using data for each 
individual participant, which limits the power to detect effect modification by individual participant 
characteristics that could potentially modify the effect of deworming (Barry et al., 2013; Turner et al., 2015). 
There are various factors that could potentially modify the effectiveness of deworming including baseline 
nutritional status (anemia and body mass index (BMI)), type of STH infection, treatment protocol, worm 
burden (particularly intensity of infection) and concomitant interventions (such as iron supplementation and 
other drugs such as praziquantel for schistosomiasis). Individual participant data (IPD) meta-analysis refers 
to analyzing data for each participant in the existing studies (Tierney, Pignon, et al., 2015; Tierney, Vale, et 
al., 2015).The advantage of an IPD analysis over aggregate meta-analysis is that it has the potential to 
improve the quality of both the data and the analyses and consequently the reliability of the results (Tierney, 
Vale, et al., 2015). Furthermore, it also provides an opportunity to re-analyze the data for the range of other 
possibilities for example, investigating the treatment effects varying by participant characteristics which is not 
possible with the aggregate data (Riley et al., 2010). An IPD approach will allow the evaluation of variation in 
effect estimates by various individual, socio-demographic and environmental factors in pregnant women that 
could potentially modify the effectiveness of deworming during pregnancy. IPD meta-analysis explores the 
question of whether mass deworming during pregnancy is more effective for subgroups of women defined 
by characteristics such as nutrition status and infection intensity. This understanding could help to develop 
targeted strategies to reach pregnant women with deworming and guide policy regarding mass deworming. 
Objective 
The objective of the review is to use IPD meta-analysis to explore whether the effects of deworming among 
pregnant women vary with individual characteristics (nutritional status, anaemia), intensity of infection (as 
assessed by egg count), infection status (including species of worm), socioeconomic status, sanitation 
environment and co-interventions. 
Methodology 
The protocol was published with the Campbell Collaboration (Salam et al., 2018) on Jun 12, 2018 and 
reported according to the preferred reporting items for systematic reviews and meta-analyses for protocols 
(PRISMA-P) (Moher et al., 2015).  Results of the review are reported using the Preferred Reporting items for 
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Systematic Reviews and Meta-analyses of individual patient data (PRISMA-IPD) Statement (Stewart et al., 
2015). 
Criteria for considering studies for this review 
We included studies that met the following eligibility criteria: 
Types of studies 
We included individually randomised controlled trials (RCT); cluster RCTs and quasi randomised studies as 
these were the most appropriate design for the IPD meta-analysis. No language or date restrictions were 
applied. 
Types of participants 
Participants were pregnant women receiving preventive or therapeutic deworming drugs for STH and 
schistosomiasis.  
Types of interventions 
We included mass deworming using any drug or a combination of drugs (including levamisole, mebendazole, 
albendazole, praziquantel and pyrantel) for STH and schistosomiasis with or without co-interventions 
compared to placebo or control (no mass deworming). Co-interventions could be food provision, micronutrient 
supplementation, iron and/or folic acid supplementation, hygiene interventions or education. We included 
studies where the co-interventions were similar in the intervention and control groups to assess the impact 
of mass deworming. 
Types of outcome measures 
The following primary and secondary outcomes were reported; however we did not use the list of outcomes 
as a criterion for inclusion of studies in the review: 
-Primary outcomes: 
 Maternal anaemia at term (haemoglobin less than 11 g/dL) 
 Maternal infection intensity (as reported by the study authors) 
-Secondary outcomes: 
 Maternal haemoglobin (Hb) at term 
 Maternal ferritin  
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 Maternal anthropometric measures (height and weight)  
 Maternal body mass index (BMI)  
 Birth weight 
 LBW (less than 2500 g)  
 Preterm birth (birth before 37 weeks of gestation)  
 Perinatal mortality (includes fetal death after 28 weeks of gestation and infant death that occurs at 
less than seven days of life)  
 Stillbirth  
 Congenital anomalies  
 Infant mortality 
Duration of follow-up 
We did not restrict inclusion based on the duration of follow-up. 
Types of settings 
The settings included any area where STH or schistosomes are endemic. These could include studies 
conducted in either community settings or facility settings including hospitals, antenatal clinics, primary 
healthcare centres etc.  
Search methods 
We conducted the search in the following databases till March 2018: MEDLINE, Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), Latin-American and Caribbean System on Health Sciences 
Information (LILACS), Excerpta Medica dataBASE (EMBASE), the Cochrane Library, Internet Documents in 
Economics Access Service (IDEAS), Google Scholar, Web of Sciences, Social Services Abstracts, the World 
Health Organization (WHO) Global Health Library, Global Health CABI and CAB Abstracts. We also searched 
grey literature in OpenGrey and websites of relevant organizations such as the World Bank, World Food 
Program and International Food Policy Research Institute. We also contacted authors of studies and 
members of our advisory board for any unpublished studies or grey literature reporting eligible studies. We 
checked reference lists of relevant studies and reviews. We also searched for trials registered with 
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ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform 
(http://www.who.int/trialsearch/). 
Titles and abstracts were screened in duplicate by two reviewers. We pilot-tested the screening criteria at 
both title and abstract screening stage and full text stage.  We used the PRISMA flow diagram to report 
eligibility of studies. We retrieved full text of all studies which pass this first level screening.  The full text 
reviews were also done in duplicate by two reviewers, and agreement was reached by consensus. 
Disagreements were resolved by consultation with a third reviewer. No language or date limits were applied. 
The search strategy is attached as Appendix 5. 
Description of methods used in primary research 
RCTs of mass deworming include two-arm trials as well as factorial trials, with women allocated either 
individually or by cluster-randomisation. 
Details of study coding categories and quality assessment  
We extracted the study characteristics including details of the populations, setting, socio-demographic 
characteristics, interventions, comparators, outcomes and study design in duplicate. Risk of bias was 
assessed at the study as well as the outcome level. At the study level, two independent reviewers performed 
quality appraisal for each study using the Cochrane risk of bias tool which assessed selection bias, 
performance bias, detection bias, attrition bias and reporting bias (Higgins et al., 2011).  Disagreements were 
resolved by discussion or consultation with a third reviewer. At the outcome level, we summarized the quality 
of evidence according to the outcomes as per the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) criteria (Walker et al., 2010). A grade of “high”, “moderate”, “low” and “very low” 
was used for grading the overall evidence indicating the strength of an effect on specific health outcome 
based on methodological flaws within the component studies, consistency of results across different studies, 
generalizability of research results to the wider patient base and how effective the treatments have shown to 
be (Balshem et al., 2011). The two reviewers discussed ratings and reached consensus. Disagreements 
were resolved by consulting a third reviewer. We developed a summary of findings table to show the effects 
for the primary outcomes of maternal anaemia and infection intensity; as well as the secondary outcomes of 
preterm birth, LBW and perinatal mortality since these outcomes assess long-term effects, particularly in 
terms of birth outcomes.    
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Data collection and analysis 
Trialists of the included trials provided IPD by electronic transfer where possible or other means as needed. 
The individual trial data were recoded as required and checked with respect to range, internal consistency, 
missing values, outliers, errors and consistency with published reports. Trial details such as randomisation 
methods and intervention details were cross-checked against published reports, trial protocols and data 
collection sheets. Inconsistencies or missing data were discussed with the individual trialists and attempts 
were made to resolve any problems by consensus. We did not exclude any study based on the way the 
outcomes were reported. 
Data were entered into a flat spread-sheet with the same fields for every study. We considered the missing 
values for each variable as missing at random (MAR). We planned to use multiple imputation to impute the 
missing values for covariates at baseline (individual participant level variables) and outcome variables 
(primary and secondary outcomes). Imputation was planned be done using Proc MI in SAS/STAT (SAS 
Institute Inc., Cary, NC, USA). We planned to assess the robustness of the results by running a separate 
model excluding imputed data (i.e. complete case analysis). However, we restricted our analysis to 
conventional complete case analyses, that is, removing subjects with a missing value from the analyses, 
since the missing data were considered to be non-trivial. Studies with missing data on more than 50% of 
outcome or covariate data were planned to be included in the complete case analysis only; however none of 
the studies were missing more than 50% of outcome or covariate data.  
Descriptive characteristics of each study were presented, with details on the participant characteristics, 
environment, worm species, prevalence, intensity of infection, geographic location, interventions, 
comparator, outcomes and risk of bias assessment. Following data items were collected: 
-Individual Level: 
 Infection intensity with Ascaris, Trichuris, hookworm and schistosomes (across four levels of none, 
light, moderate and heavy, using the WHO cutoffs for each helminth) 
 Anaemia status (using WHO cutoffs by age and altitude of non-anaemic, mild (100-109 g/l), moderate 
(70-99 g/l) and severe (lower than 70 g/l) 
 Under-nutrition (BMI<18.5 kg/m2 ) 
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 Socioeconomic status (as defined by trial authors):  We assessed whether the measurement of 
socioeconomic status can be compared across study settings and time.   
 Deworming drug used. 
 -Environmental Level: 
 WASH practices (as defined by trial authors) 
 Population level infection intensity (using WHO cut-offs for each worm-type, as above)  
We calculated the standardised difference between the published data and the IPD received from authors 
for baseline characteristics and baseline outcome assessment.  For outcome variables, we replicated the 
effect measures reported in study publications and calculated the standardised difference between the IPD 
received and the study report (Austin, 2009).  
The comparison of interest for the pairwise analysis included (but not restricted to) any deworming drug 
versus no deworming. We planned to conduct pair-wise comparisons for one deworming drug versus other 
deworming drug or a combination of deworming drugs, however we could not perform such analysis due to 
limited data. We conducted a one-stage IPD meta-analysis using random-effects multilevel meta-regression 
models to examine the interactions between the covariates and the treatment. The one-stage approach 
analyses the IPD from all studies simultaneously, for example, in a hierarchical regression model with random 
effects. The choice of one-stage IPD was pre-specified as it avoids the use of approximate normal sampling 
distributions, known within‐study variances, and continuity corrections that plague the two‐stage approach 
with an inverse variance weighting (Burke, Ensor, & Riley, 2017). Network meta-analysis is a common 
approach to synthesize the efficacy of multiple treatments, and to compare their relative efficacy, however, 
we did not plan to conduct network meta-analysis based on our previous experience with limited number of 
studies in the domain (Salam et al., 2015). We conducted pairwise analyses for each comparison of interest 
by entering all IPD data into a multilevel model, with each study as one cluster. We expected considerable 
heterogeneity between studies for each outcome; therefore, we used a random effects model. 
Where IPD was not available for all trials, we used a two-part model with one part based on IPD data and 
the second part based on aggregate data from studies which did not provide IPD (Fisher, Copas, Tierney, & 
Parmar, 2011; Riley et al., 2008; Riley & Steyerberg, 2010). We accounted for clustering as above by nesting 
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clusters within studies. We accounted for the pre-defined covariates of infection intensity, baseline anaemia, 
baseline nutritional status, socioeconomic status and maternal education in the model. 
Measures of treatment effects 
We separately analyzed the dichotomous and continuous outcomes. For dichotomous outcomes, we 
presented the results as summary risk ratios (RRs) with 95% confidence intervals (CI). We presented 
continuous outcome data as either a mean difference (MD), if outcomes have been measured on the same 
scale, or a standardised mean difference (SMD), if outcomes have been measured on different scales, with 
95% CI.   
Assessment of clinical and methodological heterogeneity within treatment comparisons 
Heterogeneity across trials in terms of subject characteristics, trial methodologies and treatment protocols 
was assessed using visual plots, tables and homogeneity statistics. We assessed heterogeneity using visual 
inspection of forest plots for pairwise analyses as well as statistical tests of heterogeneity (I2). In addition to 
I2, we also assessed between‐study variance (variation across study findings beyond random sampling error) 
by the variance of the distribution of the true study effects, commonly denoted as τ2. 
Publication bias 
We planned to generate a funnel plot for comparisons and outcomes with >10 studies. We planned to use 
Egger’s test for asymmetry and visual inspection to assess the presence of publication bias and/or selective 
reporting. However, none of the comparisons or outcomes included >10 studies and hence we could not 
assess for publication bias.  
Subgroup analyses 
Where sufficient data were available, sub-group analyses were planned to be conducted to assess effects 
across both individual-level as well as environment-level characteristics. We compared the results of models 
with subgroup analyses by assessing the size of quantitative or qualitative differences in effects, the statistical 
significance of tests for interactions, assessing between-study variance and assessing the goodness of fit of 
the models using the likelihood ratio. Before conducting subgroup analyses, we assessed the distribution of 
each variable. If there were insufficient participants in some categories, the levels were combined. The 





Where sufficient data were available, we planned to conduct sensitivity analyses to assess robustness of 
results when restricted to studies at low risk of bias for sequence generation, allocation concealment and 
blinding of participants.  We planned to assess whether results were robust to excluding imputed data (i.e. 
complete case analysis).  
Data Management  
Data were transferred to SAS as a common platform for all studies, using a common data dictionary.  We 
checked IPD data for consistency immediately upon receiving datasets for outlier individuals (e.g. with 
duplicate participant IDs, unrealistic date ranges).  We compared the IPD from authors with the aggregate 
data reported in the articles. Any missing or unusual data were flagged for discussion with the trial author or 
statistician. We asked for clarification from the authors to establish reasons for any discrepancies, and 
address them if possible.  Any requests for authors were discussed when the data were provided, such as 
clarification of trial risk of bias, conduct or eligibility criteria.  We also ran the same statistical analysis as the 
authors to check for consistency with the published paper (Stewart et al., 2015). We requested statements 
of ethics approval from each study and we did not include data from studies that had not  received ethics 
approval.  We requested that all data be transferred without any identifiers.   
Results 
Search results 
We searched all databases up to March, 2018.  Figure 4.1 provides a search flow diagram. We identified a 
total of 23,406 records through the search strategy provided in Appendix 5. A total of 31 papers (Abel et al., 
2000; Ács et al., 2005; Adam et al., 2005; Atukorala et al., 1994a; Christian et al., 2004; De Silva et al., 1999; 
Deepti & Nandini, 2015; Elliott et al., 2007; Elliott, Mpairwe, et al., 2005; Elliott, Namujju, et al., 2005; Gyorkos 
et al., 2011; Gyorkos et al., 2006; Renée Larocque et al., 2006; Liabsuetrakul et al., 2009; Millard et al., 2014; 
Tehalia, 2011c; Mpairwe et al., 2011; Nampijja et al., 2012; Juliet Ndibazza et al., 2012; J Ndibazza et al., 
2010; Ndyomugyenyi et al., 2008a; Olveda et al., 2016; Torlesse & Hodges, 2000, 2001; Tweyongyere et al., 
2009; Tweyongyere et al., 2011; Tweyongyere et al., 2008; Tweyongyere et al., 2013; Urass et al., 2011; 
Villar et al., 1998; Webb et al., 2012; Webb et al., 2011) based on 16 studies assessed mass deworming 
during pregnancy. These 16 studies were assessed for IPD eligibility and seven studies with 8515 participants 
were identified to be eligible for IPD. Table 4.1 details the study eligibility for IPD. Major reasons for exclusion 
from IPD included:  
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(i) study design not being appropriate (mainly cross-sectional and case control studies) and;  
(ii) only abstracts were available with insufficient information and the trialists could not be contacted.  




















Table 4.1: Eligibility for IPD 
Study ID Study Design Eligibility 
for IPD 
Reason for Exclusion 
Elliott 2005 (J Ndibazza et al., 2010) Randomised Controlled Trial Yes 
 
Larocque 2006 (Renée Larocque et al., 2006) Randomised Controlled Trial Yes 
 
Ndyomugyenyi 2008 (Ndyomugyenyi et al., 
2008a) 
Randomised Controlled Trial Yes 
 
Torlesse 2001 (Torlesse & Hodges, 2001) Randomised Controlled Trial Yes 
 
Urassa 2011 (Urass et al., 2011) Randomised Controlled Trial Yes 
 
Deepti 2015 (Deepti & Nandini, 2015) Randomised Controlled Trial Yes 
 
Tehalia 2011 (Tehalia 2011) Randomised Controlled Trial 
 
Only abstract available with insufficient 
information 
Villar 1998 (Villar MA, 1998) Randomised Controlled Trial 
 
Only abstract available with insufficient 
information 
Olveda 2016 (Olveda et al., 2016) Randomised Controlled Trial Yes 
 
Atukorala 1994 (Atukorala, De Silva, 
Dechering, Dassenaeike, & Perera, 1994d) 
Before-after study 
 
This was a before-after study 
Abel 2000 (Abel et al., 2000) Before-after study 
 
This was a before-after study 
Christian 2004 (Christian et al., 2004) Prospective Cohort 
 
This was a cohort study 
de Silva 1999 (De Silva et al., 1999) Cross-sectional survey 
 
This was a cross-sectional study 
ACS 2005 (Ács et al., 2005) Case-control study 
 
This was a case-control study 
Adam 2005 (Adam et al., 2005) Prospective cohort 
 
This was a cohort study 




This was a cohort study 
Characteristics of studies 
A total of seven studies including 8515 pregnant women were eligible for IPD. All of these studies were RCTs. 
Studies were conducted in India, Philippines, Peru, Sierra Leone, Tanzania and Uganda between 2001 and 
2016. The deworming drugs provided in these studies included albendazole, mebendazole, praziquantel, 
ivermectin or a combination of these. The majority of the studies provided mass deworming for STH only; 
while one study (Olveda, Acosta et al. 2016) provided deworming for schistosomiasis alone; and one study 
(Elliott, Mpairwe et al. 2005) targeted both STH and schistosomiasis. Sample sizes ranged from 184 pregnant 
women to 3080 pregnant women. The most common co-intervention was iron/folic acid supplementation 
while other interventions included food supplementation, anti-malarial drug administration and education. 
Maternal and birth outcomes were assessed in the third trimester and at the time of delivery in all the included 
studies. Table 4.2 describes the characteristics of studies eligible for IPD. Out of the seven studies, three 
trials were subsequently included in the IPD (Elliott, Mpairwe et al. 2005, Urassa, Nystrom et al. 2011, Olveda, 
Acosta et al. 2016) and further description is provided in the following sections. 
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Table 4.2: Characteristics of IPD Eligible Studies 
Serial 
no 





































Place of delivery  
HIV status 
Malaria parasites 










Immune responses in mothers 
and infants 
Maternal and perinatal 
outcomes 
Immune responses (BCG, 
tetanus, pertussis, Hep B, 
measles, diphtheria, polio, 
haemophilius) 
Co-infections (malaria, 




Growth and development (birth 




Mortality   










Single dose of 
mebendazole 
(500 mg) plus a 
daily iron 
supplement (60 
mg elemental iron, 
ferrous sulphate) 
Single dose 














Toilet facility  
Mean infant birth weight (LBW 
and VLBW) 
Maternal anaemia in third 
trimester measured by (1) 
mean Hb and (2) Hb < 11 g/dL 
Infection prevalence 
Stillbirth 








































Group A (n = 198) 
received 
ivermectin 
Group B (n = 194) 
received 
albendazole (a 
single dose of 400 
mg) 









package with iron 
supplements 
Group D (n = 


















Mean parasite density 
Neonatal anemia  





















urban and 6 






Albendazole, 2 x 
200 mg, single 
dose, at first 









vitamin D were 




tablets (1.25 as 
ferrous 
gluconate and 5 
mg folic acid 
started at first 





mg), 1 daily, 
were chosen as 
the control for 
iron-folate 
supplements 
Hb Worm prevalence  
Anemia  
Iron deficiency anemia 
Cure rate 
Egg reduction rate 










(400mg) (given at 
term and 4 
months later) 
Daily iron folate 
supplements 
Placebo  Parity  
Gestational age 

































6.  Deepti 2015 Randomised 
Controlled 
Trial 






mebendazole   




Baseline infestation  
Maternal anemia  
Worm intensity 
Worm prevalence  
Birth weight  
Low birth weight   












dose 60 mg/kg 
given 
as two split doses) 











Maternal weight gain 
Treatment success 
Cure rate  
Maternal adverse events 
Congenital anomaly 




Quality of Studies 
The quality of the studies was assessed using the Cochrane risk of bias assessment criteria. Overall, the 
included studies were judged to be of fairly good quality. For random sequence generation, five studies were 
judged to be at low risk of bias while two studies (Ndyomugyenyi, Kabatereine et al. 2008, Urassa, Nystrom 
et al. 2011) were rated as unclear since the method of sequence generation was not specified. Allocation 
concealment was judged to be adequately done in three studies (Elliott, Mpairwe et al. 2005, Larocque, 
Casapia et al. 2005, Deepti and Nandini 2015); four studies did not clearly specify the concealment of 
allocation and were judged to be at unclear risk (Torlesse and Hodges 2000, Ndyomugyenyi, Kabatereine et 
al. 2008, Urassa, Nystrom et al. 2011, Olveda, Acosta et al. 2016). All the included studies either adequately 
blinded the participants, personnel and outcome assessors or we felt that lack of blinding would be unlikely 
to affect the results and hence all the studies were rated to be at low risk for blinding. Four studies were rated 
at low risk of attrition bias while two studies were rated to be at high risk of attrition bias (Torlesse and Hodges 
2000, Urassa, Nystrom et al. 2011). All the studies were judged to be at low risk of bias for selective reporting 
since the outcomes specified in the study protocol or methodology section of the study were reported in the 
outcome section. We judged one study as unclear risk of bias for ‘other bias’ since in the (Elliott, Mpairwe et 
al. 2005) study, enrolment was stopped after 104 women due to new guidelines by the WHO which 
recommended inclusion of treatment of women with schistosomiasis. Figure 4.2 depicts the risk of bias for 
















Contacting authors and yield of the studies 
Trial authors were contacted for all seven trials deemed eligible for the IPD. Out of the seven trials, we 
received data from three trials (Elliott, Mpairwe, et al., 2005; Olveda et al., 2016; Urassa et al., 2011); data 
from two trials were lost (Deepti & Nandini, 2015; Torlesse & Hodges, 2000) (trialists were not able to retrieve 
the data); one trialist refused to share the data (Larocque et al., 2006) while one could not be contacted due 
to severe health conditions (Ndyomugyenyi et al., 2008). In terms of the number of participants; out of 8515 
potential IPD participants; data were captured for 5957 participants (70%). Figure 4.3 depicts the number of 
studies and participants eligibility for IPD.  




No. of studies: 3
2
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Received Lost Refused No response





Received Lost Refused No response
Total number of Participants (N=8515)
93 
 
Data Preparation: Missingness analysis 
Table 4.3 and 4.4 provides an overview of the missing values for the baseline and endpoint variables in the 
data sets from each of the trial.  
Table 4.3: Missing values for baseline variables 









Education 0.15% (4) 0.55% (2) NA 0.1% (6) 
Parity NA 0% 0% 0% 
Gravidity 0% NA 0% 0% 
Weight 0.15% (5) 0% NA 0.08% (5) 
Height 1.12% (28) 0% NA 0.5% (28) 
Anaemia 0.5% (12) 0% 0% 0.2% (12) 
S.Japonicum Intensity NA 0% NA 0% 
S.Mansoni Intensity 0% NA NA 0% 
A.Lumbricoides 
Intensity 
NA 39% (141) NA 2.4% (141) 
T.Trichiura Intensity 0% 19% (69) NA 1.15% (69) 
Hookworm Intensity 0% 64% (231) NA 3.88% (231) 
Ascaris Intensity 0% NA NA 0% 













Table 4.4: Missing values for endpoint variables 









Maternal Weight NA 0.82% (3) NA 0.05% (3) 
Anaemia 13.53% (339) 0.82% (3) 12.51% (385) 12.23% (727) 
S.Japonicum Intensity NA 63.5% (230) NA 3.87% (230) 
S.Mansoni Intensity 18% (451) NA NA 18% (451) 
A.Lumbricoides 
Intensity 
NA 0% NA 0% 
T.Trichiura Intensity 18% (451) 26% (94) NA 9.17% (545) 
Hookworm Intensity 18% (451) 0% NA 18% (451) 
Ascaris Intensity 18% (451) 0% NA 18% (451) 
Birth weight 23.91% (599) 0.27% (1) NA 10.1% (600) 
LBW 23.91% (599) 0.27% (1) NA 10.1% (600) 
Preterm Birth 6.38% (160) 0% NA 2.7% (160) 
 
Data Replications  
Replication of the published study results was conducted for all three studies. The standardised differences 
between the published and replication results were all below 0.10 for all outcome measures and covariates. 
There were instances where the standardised difference could not be calculated because the published 
results did not report the outcome measure in question. Table 4.5 reports the standardised differences 








Table 4.5: Standardised differences between published and reproduced results for outcome 
measures by eligible studies 
Variables Studies 
 Elliott 2005 Olveda 2016 Urassa 2011 
Maternal weight  NA 0.00 NA 
Maternal anaemia 0.02 NA 0.00 
Maternal haemoglobin  0.74 0.005 NA 
S. Japonicum intensity  NA NA NA 
S. Mansoni intensity  0.00 NA NA 
Ascaris intensity  0.00 NA NA 
Trichuris intensity  0.04 NA NA 
Hookworm intensity  0.00 NA NA 
Birth weight 0.007 0.003 NA 
LBW 0.05 0.05 NA 
SGA NA 0.00 NA 
Preterm birth NA NA NA 
Perinatal mortality 0.00 NA NA 
Congenital anomaly  0.01 NA NA 
Infant survival NA NA NA 
 
IPD feasibility and changes to the analysis model 
Based on the availability of data, we could only analyse one comparison of interest (mass deworming with 
any drug versus no mass deworming). The planned analysis and final model was also modified accordingly. 











Table 4.6: Comparison of the original analysis plan and actual model employed 
 Planned Analysis Actual Analysis 
Outcomes  Maternal anaemia at term  
Maternal infection intensity  
Maternal haemoglobin at term 
Maternal ferritin  
Maternal anthropometric measures  
Maternal BMI 
Birth weight 
Low birth weight  
Preterm birth  
Perinatal mortality  
Stillbirth  
Congenital anomalies  
Infant Mortality 
Maternal anaemia at term  




Covariates  Schistosoma egg count 
Ascaris egg count 
Hookworm egg count  
Trichuria egg count 
Haemoglobin   
BMI  
Socio-economic status  
Deworming drug  
WASH practices 
Population level worm intensities  
Hookworm egg count  
Trichiura egg count 
Haemoglobin  
Effect Modifiers  BMI (<18.5 kg/m2 , 18.5 to 25 kg/m2) 
Anaemia status (none, mild, moderate, 
severe) 
Schistosoma intensity (light, moderate, 
heavy) 
Ascaris intensity (light, moderate, heavy) 
Hookworm intensity (light, moderate, heavy) 
Trichuria intensity (light, moderate, heavy) 
Any STH or Schistosoma infection (light, 
moderate, heavy) 
Concomitant interventions 










Main effects  
This section provides the overall results for mass deworming compared to no mass deworming on the 
following outcomes: maternal anaemia; maternal infection intensity (T.Trichiura and hookworm); LBW and 
preterm birth. We report results for the evidence from study results pooled at the aggregate level (adjusted 
for covariates) and the evidence pooled using IPD (adjusted for covariates). However we advise caution in 
interpreting these findings due to small sample sizes. Following this section, we describe effect modifier 
analyses for each planned effect modifier for each outcome of interest. 
-Maternal anaemia: The effect estimates from aggregate evidence were of similar size and direction as 
the IPD effect estimates. Three trials reported data on maternal anaemia. Mass deworming led to a 23% 
reduction in maternal anaemia (RR: 0.77, 95% CI: 0.73-0.81; three trials; 5216 participants; moderate quality 
evidence). Table 4.7 reports the aggregate and IPD adjusted estimates.  
Table 4.7: Impact of mass deworming on maternal anaemia 
Analysis Effect estimates (RR and 95% CI) 
Aggregate adjusted 0.94 (0.89-0.99) 
IPD adjusted 0.77 (0.73-0.81) 
 
-T.Trichiura intensity: Two trials reported T.Trichiura intensity showing no impact of mass deworming on 
any infection (RR: 0.69, 95% CI: 0.42-1.13; two trials; 2867 participants; moderate quality evidence). We 
attempted to categorize the participants according to the intensity of infection (none, light, moderate and 
heavy); however there were too few participants in each category to draw meaningful conclusions. The effect 
estimates from aggregate evidence were of similar size and direction as the IPD effect estimates. Table 4.8 
reports the aggregate and IPD adjusted estimates for maternal T.Trichiura intensity.  
Table 4.8: Mass deworming on T.Trichiura intensity (any infection) 
Analysis Effect estimates (RR and 95% CI) 
Aggregate adjusted 1.06 (0.87- 1.30) 





-Hookworm intensity: Two trials reported hookworm intensity. Overall there was no impact of mass 
deworming on any hookworm infection (RR: 0.52, 95% CI: 0.18, 1.47; two trials; 2867 participants; moderate 
quality evidence). We attempted to categorize the participants according to the intensity of infection (none, 
light, moderate and heavy); however there were too few participants in each category to draw meaningful 
conclusions. The effect estimates from aggregate evidence were of similar size and direction as the IPD 
effect estimates. Table 4.9 reports the aggregate and IPD adjusted estimates for maternal hookworm 
intensity. 
Table 4.9: Mass deworming on hookworm intensity (any infection) 
Analysis Effect estimates (RR and 95% CI) 
Aggregate direct adjusted 0.39 (0.04 - 3.93) 
IPD direct adjusted 0.52 (0.18-1.47) 
 
-Low Birth Weight: Two trials reported LBW suggesting no impact of mass deworming on LBW (RR: 0.89, 
95% CI: 0.67-1.18; two trials; 2267 participants; moderate quality evidence). Table 4.10 reports the aggregate 
and IPD adjusted estimates for LBW. 
Table 4.10: Mass deworming on LBW 
Analysis Effect estimates (RR and 95% CI) 
Aggregate direct adjusted 1.04 (0.79, 1.38) 
IPD direct adjusted 0.89 (0.67, 1.18) 
 
-Preterm Birth: Two trials reported preterm birth suggesting no overall impact (RR: 0.69, 95% CI: 0.47-
1.03; two trials; 2707 participants; moderate quality evidence). Table 4.11 reports the aggregate and IPD 
adjusted estimates for preterm birth.  
Table 4.11: Mass deworming on preterm birth 
Analysis Effect estimates (RR and 95% CI) 
Aggregate direct adjusted 0.84 (0.51, 1.39) 




Effect modifier analyses 
Based on the availability of the data, we could only assess for effect modification by baseline Trichiura 
infection, maternal anemia at baseline and maternal BMI at baseline. The overall model suggested overall 
reduction in maternal anemia (RR: 0.77, 95% CI: 0.73-0.81) with no impact on Trichiura infection, hookworm 
infection, LBW and preterm birth. There was no evidence of effect modification by baseline Trichiura infection, 
maternal anaemia at baseline and maternal BMI at baseline. Table 4.12 depicts the estimates for full model 
and effect modification. 
The outcomes were rated to be of moderate quality due to study limitations. Further studies accounting for 
maternal baseline worm intensities, concomitant iron/folic acid supplementation and antenatal care coverage 
could change our findings. These findings are summarized in the summary of findings table (Table 4.13).   
 
Table 4.12: Potential effect modification of mass deworming during pregnancy by baseline infection 
intensity, anaemia status, and BMI 
 Categories Outcomes (RR with 95% CI) 










 0.77 (0.73-0.81) 0.69 (0.42, 1.13) 0.52 (0.18, 1.47) 0.89 (0.67-1.18) 0.69 (0.47-1.03) 
Trichiura 
Intensity  at 
baseline 
Not infected 0.93 (0.80-1.09) - - 0.67 (0.43-1.04) 0.82 (0.50-1.36) 




Normal - 0.65 (0.53-0.81) 0.51(0.42-0.62) 0.80 (0.56-1.13) 0.57 (0.36-0.92) 
 Anaemia (Hb 
<11 g/dl) 
- 0.60 (0.46-0.78) 0.56 (0.45-0.70) 1.01 (0.68-1.49) 0.71 (0.41-1.22) 
Maternal BMI 
at baseline 
Normal 0.88 (0.77-1.01) 0.61 (0.51-0.73) 0.49 (0.42-0.57) 0.86 (0.65-1.15) 0.72 (0.48-1.09) 
 Low (<18.5 
kg/m2) 





Table 4.13: Summary of findings table 
Mass deworming for STH and Schistosomiasis during pregnancy compared to placebo   
Population: Pregnant women  
Setting: Low- middle- income countries of Uganda, Tanzania and Philippines  
Intervention: Mass deworming with any drug 
Comparison: Placebo  
Outcomes No of 
Participants 
(Studies)  
Aggregate evidence  IPD evidence  
  RR (95% CI) Quality of the 
evidence (GRADE) 















(2 studies) 1.06 (0.87- 1.30) 
⊕⊕⊕⊝ 
Moderate1 






(2 studies) 0.39 (0.04 - 3.93) 
⊕⊕⊕⊝ 
Moderate1 
0.52 (0.18-1.47) ⊕⊕⊕⊝ 
Moderate1 
LBW 2267  
(2 studies) 
1.04 (0.79 -, 1.38) 
⊕⊕⊕⊝ 
Moderate1 
0.89 (0.67, 1.18) ⊕⊕⊕⊝ 
Moderate1 
Preterm birth  2707  
(2 studies) 
0.84 (0.51 - 1.39) 
⊕⊕⊕⊝ 
Moderate1 
0.69 (0.47, 1.03) ⊕⊕⊕⊝ 
Moderate1 
STH: soil transmitted helminths; RR: risk ratio; CI: confidence interval; LBW: low birthweight  
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and 
may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is 
likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 










Discussion and Conclusion 
This IPD meta-analysis is based on the data from three trials with 5957 participants. The effect estimates 
from aggregate evidence were of similar size and direction as the IPD effect estimates. Findings from this 
IPD suggest reduction in anaemia among pregnant women with mass deworming. The reduction in anaemia 
could be attributable to the concomitant iron supplementation in one study since one of the three trials 
included in the IPD analysis provided daily iron folate supplements (36mg iron; 5mg folate) along with the 
deworming drugs. There was no effect on any of the other outcomes including Trichiura infection, hookworm 
infection or any of the pregnancy outcomes including LBW and preterm birth. Findings of no impact of mass 
deworming on infection intensity could be attributable to the fact that majority of the study population in the 
included studies were either not infected or lightly infected which could have diluted the impact. Based on 
the availability of the data, we could only assess for effect modification by baseline Trichiura infection, 
maternal anemia at baseline and maternal BMI at baseline. There was no evidence of effect modification by 
Trichiura intensity at baseline, maternal anaemia at baseline and maternal BMI at baseline; however we 
advise caution in interpreting these findings due to limited number of participants included in the analysis. 
Findings from this IPD analysis is based on 70% of the existing data deemed eligible for IPD (5957 
participants of 8515 participants). The studies included in this review were conducted among pregnant 
women in LMIC settings. One of the three trials included in the IPD analysis provided daily iron folate 
supplements (36mg iron; 5mg folate) along with the deworming drugs. The trials included in the IPD were 
judged to be of fairly good quality except one study judged to be at high risk of attrition bias and one study 
lacked allocation concealment. The overall outcome quality was judged to ‘moderate’ based on the GRADE 
criteria. The outcome quality was downgraded since the estimates are based on 70% of the eligible IPD data. 
Despite receiving the majority of the existing data (70%) to conduct the IPD, there were a few limitations. 
One limitation of this review is that we did not receive data from all eligible studies. Two major reasons for 
not receiving data were lost data and refusal. In the context of IPD, responsible data sharing is imperative to 
support efficient research and generate new knowledge. Another limitation is that we were unable to assess 
effect modification by pre-specified effect modifiers. The trials did not capture many of the variables of interest 
that restricted our analysis. Very few trials reported outcomes according to the baseline level of infection 
intensities and hence those conclusions could not be drawn. In terms of the infection intensities, the 
population studied were either not infected or lightly infected and hence it was difficult to categorize the 
sample according to the intensity of infection and have meaningful estimates. Trials did not report baseline 
data on the individual and environmental level effect modifiers and hence it was difficult to assess the effect 
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modification. Variables like socio-economic status were least studied and where reported, had different 
definitions and hence could not be accounted for. None of the included studies assessed any co-interventions 
including WASH practices and hence the impact of co-interventions could not be assessed. Future research 
accounting for baseline worm intensities, concomitant iron/folic acid supplementation and antenatal care 
coverage could change these findings. We could not assess for publication bias given the small number of 
included studies; however, considering the small universe of studies in the domain, the issues related to 
publication and small study sizes cannot be ignored.   
The most recent Cochrane meta-analysis (Salam, Haider et al. 2015) on deworming for STH during 
pregnancy concluded that there was insufficient evidence to recommend deworming for STH. This review 
also highlighted the need for future well-designed, large scale RCTs to establish the benefit. These findings 
were based on four trials including 4265 participants. This review has some differences compared to our 
review. The inclusion criteria for this Cochrane review was limited to deworming for STH alone while our IPD 
meta-analysis also included trials with deworming for schistosomiasis. The Cochrane review reported no 
impact of mass deworming for STH on maternal anaemia while findings from our review suggests reduction 
in maternal anaemia associated with mass deworming,   
There is a need to evaluate mass deworming for STH and schistosomiasis during pregnancy in large scale 
programmatic settings. Future impact evaluations should attempt to measure various individual and 
environmental factors that could potentially affect the impact of mass deworming. Future program evaluations 
should also assess the long term impact of mass deworming on birth and infant health outcomes along with 
the maternal health outcomes. There is an urgent need for open data from all research studies. The quality 












The World Health Organization (WHO) identifies three population groups at high risk for soil transmitted 
helminthiases (STH) and schistosomiasis including school-age children (SAC), pre-SAC, and girls and 
women of reproductive age (WRA). The case for schistosomiasis is relatively straightforward; however, more 
recently there has been some debate around the effectiveness of mass deworming for STH. Historically, 
much attention has been devoted to targeting SAC and pre-SAC through large-scale routine mass deworming 
programs for the prevention and management of STH. Children have been the main focus of mass 
deworming since schools provide a favourable delivery platform to target SAC and achieve high program 
coverage, making these programs more cost effective. In contrast, there has been little information on 
deworming programs specifically targeting WRA and hence there is a consequent gap in the evidence related 
to the health impacts, program coverage and potential cost-effectiveness related to mass deworming for 
WRA. However, this appears to be changing as new plans are being discussed by the WHO to include WRA 
in deworming activities. This chapter discusses the current guidelines on mass deworming for WRA, the 
challenges with the current recommendations, the economic perspective of mass deworming for WRA and 











Mass Deworming: WRA remains a neglected group  
The World Health Organization (WHO) identifies three population groups at high risk for soil transmitted 
helminthiases (STH) and schistosomiasis including school-age children (SAC), pre-SAC, and girls and 
women of reproductive age (WRA) (WHO, 2006). A recent estimation suggests that approximately 688 million 
girls and WRA are at risk of STH infection; including 140 million pregnant and lactating women and another 
108 million adolescent girls (Mupfasoni et al., 2018). Approximately 40 million WRA are infected with 
schistosomiasis (Friedman et al., 2007; Nour, 2010). Geographically, the regions of south-east Asia and 
Africa have the highest numbers of each WRA subgroup at risk of STH, accounting for 74.7% of all STH at-
risk WRA (Mupfasoni et al., 2018). 
Historically, much attention has been paid to target pre-SAC and SAC for the prevention and management 
of STH and schistosomiasis through mass deworming programs (periodic treatment of large groups of people 
with deworming drugs disregarding their status of infection). These mass deworming programs have been 
facilitated mainly through pharmaceutical drug donations, large-scale national deworming programs and 
global reporting systems (Mofid & Gyorkos, 2017). The initial focus of the large-scale deworming programs 
have been SAC owing to the fact that this age group was at high risk of morbidity from STH infections and 
the pharmaceutical companies provided the single-dose deworming medicines free of charge. Additionally, 
schools provide a favourable delivery platform to target pre-SAC and SAC and achieve high program 
coverage, making these programs more cost effective along with providing a convenient sampling frame for 
surveillance (Anderson, Turner, Truscott, Hollingsworth, & Brooker, 2015). The current WHO guidelines focus 
on SAC, both for monitoring infection and as a target for treatment, although treatment of pre-SAC and WRA 
is also recommended where sustainable delivery mechanisms exist, especially in areas of intense 
transmission (Anderson et al., 2015). 
In contrast, there has been little information in either the published or unpublished literature on deworming 
programs specifically targeting WRA. A recent review evaluating the impact of mass deworming among non-
pregnant adolescent girls and adult women identified sparse data from four trials with moderate to very low 
quality of evidence (Ghogomu et al., 2018). Moreover, in some settings it has proven difficult to achieve high 
coverage and good surveillance among adults for mass deworming. WRA were initially included as a part of 
the community-based mass deworming programs under the Global Programme to Eliminate Lymphatic 
Filariasis (GPELF) in 2000, whereby all individuals in a household except pregnant women were eligible for 
deworming. There have been other reports of deworming in WRA, but these have either been within particular 
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research projects or in limited geographical areas within specific countries. The WHO Preventive 
Chemotherapy Databank reports on deworming coverage for pre-SAC and SAC; however, no coverage 
estimates are available for deworming in WRA, and few countries include this risk group among deworming 
activities (WHO, 2018). In fact, the disease burden of STHs in WRA is largely unknown (Mofid & Gyorkos, 
2017). It has been estimated that coverage rates for WRA within GPELF, on an annual basis, approximates 
20% of all at-risk WRA (WHO, 2018). Although WRA may have indirectly benefited from mass deworming 
targeting children living in the same household, this group has been neglected and consequently they have 
not been able to get the direct benefits of treatment (Mofid & Gyorkos, 2017).  
Current guidelines  
Currently, mass deworming is recommended as an effective strategy to prevent and treat STH and 
schistosomiasis. The most recent recommendations by the WHO on deworming among pregnant women 
(WHO, 2017) recommends preventive chemotherapy (mass deworming), using single-dose albendazole (400 
mg) or mebendazole (500 mg), as a public health intervention for pregnant women including pregnant 
adolescent girls after the first trimester (in the second or third trimester), living in areas where both:  
(i) the baseline prevalence of hookworm and/or T. trichiura infection is ≥ 20% among pregnant 
women, and  
(ii) where anaemia is a severe public health problem, with a prevalence of ≥ 40% among pregnant 
women. 
For schistosomiasis, annual treatment with praziquantel in high risk communities (>50% prevalence) and 
once every two years in medium risk communities (>10% and <50% prevalence) is recommended. Women 
can be treated with praziquantel at any stage of pregnancy and lactation (WHO, 2006). 
Challenges with the current recommendations 
More recently, there has been a lot of discussion around routine mass deworming programs and their 
effectiveness has been questioned since the recent evidence synthesis suggested that these programs have 
very little or no benefit for children and pregnant women ( Bundy et al., 2018; Salam et al., 2015; Turner et 
al., 2015; Welch et al., 2016). The key area for debate around mass deworming is not whether deworming 
medicine works but whether the benefits of deworming exceed the costs or whether it would be more prudent 
to invest in other interventions including education, sustainability of WASH programs, communication to 
encourage high treatment uptake and better integration of STH control with other relevant programs with 
existing wide-spread coverage (Anderson et al., 2015; Bundy, Kremer, Bleakley, Jukes, & Miguel, 2009). 
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Deworming drugs such as levamisole, mebendazole, albendazole, praziquantel and pyrantel have been 
reported to be efficacious with minimal side-effects (WHO, 1994, 2018) but a critical issue in evaluating 
current STH policies concerns who to treat, how frequently to treat, and how long to treat (Anderson et al., 
2015).  This section discusses the issues and gaps around the existing mass deworming guidelines with a 
closer look on issues specific to pregnant women and WRA.  
Broadly, the field of neglected tropical diseases (NTDs) lags behind in terms of model development and 
parameter estimation and much of the existing treatment mechanisms are largely based on discussion and 
consensus, without detailed calculations (Anderson et al., 2015). The fact that the transmission cycle for STH 
is a dynamic process has hardly been considered in the existing research evidence and implementation 
programs. The fact that all intestinal worms are not the same; that not all intestinal worms respond to the 
same deworming medication; and that not all infested individuals exhibit the disease is hardly specified. 
Although existing studies have shown that treatment of some individuals lead to a reduction in transmission 
in the community as a whole; these studies do not adequately address the population dynamics of STH 
infection (Bundy et al., 2009). The majority of the studies on deworming have followed standard practice in 
clinical trials and considered untreated people as a control group. Since the current studies have been 
conducted in areas where most people have low to moderate intensity infection rather than high intensity 
infection, there is a potential for considerable and unknown variance in the intensity of individual infection. 
Consequently the intensity is unknown in any individual, as is the likelihood of morbidity and the potential 
scale of benefit from treatment. Such studies tends to average out the effectiveness when population as a 
whole is studied rather than studying population subgroups with varying intensity of infections (Bundy et al., 
2018).   
Another critical issue concerns the reach of these drugs to infected geographical pockets and the lack of 
focus on concomitant transmission control strategies like water, sanitation and hygiene (WASH) 
interventions. At present, many countries with endemic STH infections are not availing themselves of the 
freely donated drugs to treat children, partly due to the logistical challenges in getting the drugs to these 
populations. With this existing situation, the expansion of these programs to target WRA would also require 
an increase in drug donations as well as effective targeting platforms to achieve high program coverage for 
WRA. Even if the mass deworming coverage targets are reached, it might not be enough to eliminate 
transmission and the focus should be concomitant morbidity control, and ideally, the eventual elimination of 
transmission (Anderson et al., 2015). Consequently it is highly desirable to modify the existing guidelines with 
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a concomitant emphasis on education and sustainability of current WASH programs along with mass 
deworming to reduce transmission intensity and thereby enhance the impact of mass deworming programs 
(Anderson et al., 2015). 
With regards to mass deworming during pregnancy, the data about the deworming drug use in pregnancy 
are scarce (WHO, 1994, 2018). Adverse events associated with deworming in girls and women themselves 
have rarely been published, and usually only within the context of specific research studies (Keiser & 
Utzinger, 2008; Ndyomugyenyi et al., 2008). Although mass deworming is regarded as the most effective 
means of controlling morbidity and mortality with STH; the long-term safety when administered during 
pregnancy, particularly in terms of birth outcomes has not been rigorously evaluated (WHO, 1994, 2018). 
However, serious adverse events have not been reported (Ndyomugyenyi et al., 2008a). A recent review 
investigating the scope of available evidence for benefits of deworming treatments in order to inform a 
decision about possible inclusion of deworming as an intervention in the Lives Saved Tool (LiST) found that 
deworming did not show consistent benefits for indicators of mortality, anaemia, or growth in children younger 
than five or WRA and hence did not recommend including deworming in the LiST model (Thayer, Clermont, 
& Walker, 2017). These concerns are further complicated by the lack of evidence supporting the health 
benefits of treating helminths during pregnancy on maternal and birth outcome (Salam et al., 2015). 
Consequently, there is the question of undue exposure to deworming drugs as a result of routine mass 
deworming and the potential adverse effects on the foetus. Another barrier to including WRA in mass 
deworming programs is likely the fear of inadvertently administering deworming drugs to women who may 
not be aware that they are in their first trimester of pregnancy (at which time deworming in contraindicated) 
since a comprehensive approach for targeting WRA is currently lacking (Mofid & Gyorkos, 2017). 
More recently, issues related to limited efficacy profiles of albendazole, mebendazole, levamisole, and 
pyrantel pamoate have also been raised with some evidence supporting co-administration of some 
deworming drugs (Moser et al., 2017; Palmeirim et al., 2018). Furthermore, there are issues related to drug 
resistance associated with the scale-up of periodic mass deworming campaigns (Moser et al., 2017; 
Palmeirim et al., 2018).  
Economic Perspective 
From an economic policy perspective, the merits of mass deworming depend mainly on whether its long-term 
impact on earnings exceeds its cost. Deworming costs very little at about US$0.25 per child per year and a 
consequent high benefit to cost ratio. The cost effectiveness of targeting WRA with mass deworming 
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programs poses a different issue since there are no existing delivery platforms targeting WRA that might be 
as cost-effective and convenient as schools for targeting children (Anderson et al., 2015) and the cost of 
treating WRA might at times be higher when compared to SAC due to the ease of targeting children through 
school based platforms. Moreover, existing cost studies for deworming among WRA are scarce and mainly 
evaluate the cost of specific integrated delivery mechanism for deworming WRA. Cost studies for deworming 
among WRA suggest that implementation costs vary primarily by the type of delivery strategy used. 
One study (Boselli et al., 2011)  investigated the cost of the provision of anthelminthic drugs during existing 
immunization campaigns for Expanded Programme on Immunization (EPI) in Laos. The integrated delivery 
of mass deworming with the existing EPI reduced the individual cost of deworming by 10 times (from US$0.25 
in the vertical deworming campaign to US$0.02 in the integrated campaign) compared to implementation of 
the vertical deworming campaign alone. Burden posed on health workers by the integration process was 
perceived as minimal and manageable. Besides, delivery of anthelminthic drugs during the immunization 
campaigns enabled campaign teams to directly observe drug intake, which assured safety. Such an 
integration was estimated to be cost-effective due to the shared use of resources (like campaign venues and 
the meeting opportunities as well as the simultaneous mobilization of communities, health workers and social 
mobilization teams) along with the non-remuneration of health workers for the additional time dedicated to 
deworming training and activities in the context of the integrated campaign. Furthermore, the deworming 
programs can potentially benefit from the existing high coverage of the EPI programs. According to the WHO 
and the United Nations International Children's Emergency Fund (UNICEF) immunization summary, EPI has 
already achieved at least 75% national coverage in over 90% of the STH-endemic countries in the world 
which could potentially increase the national coverage of deworming for WRA (Boselli et al., 2011). 
Another study (Casey et al., 2011) estimated the cost and cost-effectiveness of a project administering 
deworming and weekly iron-folic acid supplementation to control anaemia among WRA in Yen Bai province, 
Vietnam. Cost effectiveness was evaluated using data on programmatic costs based on two surveys in 2006 
and 2009 and impact on anaemia and iron status collected in 2006, 2007, and 2008. The cost per woman 
treated (defined as consuming at least 75% of the recommended intake) was USD 0.76 per annum. This 
estimate includes financial costs (for supplies, training), and costs of health care workers’ time. The cost-
effectiveness of the project was reported to be USD 4.24 per anemia case prevented per year. Based on 
estimated productivity gains for adult women, the benefit: cost ratio was 6.7:1. Cost of the supplements and 
deworming drugs was 47% of the total, while costs of training, monitoring, and health workers’ time accounted 
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for 53%.  This study demonstrated the effective uptake of weekly iron-folic acid supplementation by 70% of 
woman in Yen Bai province with an annual cost of USD 0.76/woman. This compares to estimates by the 
National Institute of Nutrition that only 20% of pregnant women are covered by the national antenatal program 
of daily iron supplementation for which there is no costing. This study concluded that weekly iron-folic acid 
supplementation and regular deworming is a low-cost and cost-effective intervention and would be 
appropriate for population-based introduction in settings with a high prevalence of anaemia and iron 
deficiency and low malaria infection rates (Casey et al., 2011). 
One study (Lee, Bacon, Bailey, Wiringa, & Smith, 2011) assessed the effectiveness of hookworm vaccine 
and suggested that the vaccine would be strongly cost-effective (and in many situations economically 
dominant) especially when combined with a drug treatment program over a range of vaccine efficacies, 
vaccine costs, and hookworm rates. The model has demonstrated that incorporating vaccination into current 
hookworm drug treatment strategies targeting SAC and WRA may yield benefit at minimal cost. However, 
the findings suggest that while interventions were cost-effective for both SAC and WRA, the coverage and 
therefore economic return for targeting SAC may be greater and hence SAC may be an initial target for 
vaccination initiatives with subsequent expansion to WRA. The authors caution that this may vary with 
environmental conditions and infection risk among these groups. Less additional benefit may be seen with 
the initiation of vaccination in regions where infection prevalence is still able to be controlled through drug 
treatment. Low cost of anthelminthic drugs currently available make the cost-effectiveness of local vaccine 
distribution contingent upon the current drug efficacy present within the community. Findings warrant future 
studies that explore the implications of the introduction of a hookworm vaccine into other countries (Lee et 
al., 2011). 
What’s the way forward?  
WRA have historically not been a focus of the deworming programs and hence there is a consequent gap in 
the evidence related to the health impacts, program coverage and potential cost-effectiveness related to 
mass deworming for WRA. However, this appears to be changing as new plans are being discussed by the 
WHO to include WRA in deworming activities (WHO, 2018). The recent report of the WHO Advisory Group 
on deworming in girls and WRA shows a renewed focus of deworming for WRA; although it does not answer 
some of the critical questions and highlight some issues as research priorities. Critical issues requiring more 
focus include: when to stop the deworming programs; ideal delivery strategies and platforms to target WRA; 
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cost-effectiveness of deworming programs with or without iron supplementation; and supplementary benefit 
of interventions other than deworming and its cost-effectiveness. 
Although the existing deworming guidelines clearly specify the geographic prevalence cut-offs for mass 
deworming implementation; however, it does not take into account the infection intensities among various 
population groups and the existing deworming coverage. Along with mass deworming, various strategies to 
help identify pockets with high infection intensity, communities nearing elimination and those needing further 
interventions, should also be applied simultaneously. Geospatial and spatio-temporal analysis could help 
identify geographical areas where mass deworming still needs to be implemented and where these programs 
should now conclude. This will help the country level program implementers gauging the program success 
and coverage along with deciding on the future of the program.    
There is a need to identify the most appropriate platforms, strategies, and target groups that need to be 
considered while planning for deworming for WRA. Antenatal clinics could be one of the potential delivery 
platforms to target pregnant and lactating women while existing community health programs could be 
potentially utilized to reach WRA in the community. Without much data to support deworming programs for 
WRA, it is imperative to assess the relative costs and cost-effectiveness of various potential strategies and 
platforms. With respect to deworming during pregnancy, it is of prime importance to treat pregnant women in 
the second and third trimester of pregnancy and hence measures to correctly and cost-effectively identify 
and exclude women in the first trimester of pregnancy also needs to be explored. There is a need to identify 
specific process and outcome indicators for mass deworming programs targeting WRA since these would 
largely vary from the existing SAC deworming programs. More specifically, the coverage goals and the 
morbidity reduction goals need to be specified for the specific subgroups of WRA including adolescent girls, 
pregnant and lactating women. 
Further empirical evidence of impact of maternal infections with STH on health of infants and children need 
to be further explored. Moreover, the health benefits of treating pregnant women with deworming drugs for 
mother and infants needs exploration. Safety of mass deworming for the various subgroups of WRA, except 
pregnant women also need to be studied. Research on the benefits of maternal postpartum deworming is 
urgently needed to build on the deworming  (Mofid & Gyorkos, 2017). There is a need to study the 
effectiveness of maternal postpartum deworming as a means to improve both maternal and child health. 
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Concomitantly, there is a need to broaden the scope of research to investigate the cost-effectiveness and 
feasibility of alternative treatment strategies in achieving the interruption of transmission across a range of 
settings. The debate on what is the best strategy to manage STH infection should shift from prevention and 
management to morbidity control and transmission interruption. It is highly desirable to shift the focus from 
deworming alone and include concomitant emphasis on education and sustainability of current WASH 
programs to reduce transmission intensity and thereby enhance the impact of existing mass deworming.  
Possible future studies should assess the effectiveness of large scale implementation evaluations along with 
measuring and controlling for possible confounding variables including concomitant iron/folic acid 
supplementation, antenatal care coverage and WASH interventions. It is imperative to assess the outcomes 
that are programmatically relevant and contribute to the Global Burden of Diseases in a non-randomised 
setting. Due attention should be given to sustainability of the current WASH programs along with mass 















Chapter 6: Overall Conclusions 
 
Abstract 
Mass deworming remains the recommended strategy to prevent and treat STH and schistosomiasis. Findings 
from the systematic review assessing mass deworming during pregnancy suggests that it does not have any 
impact on maternal anemia; however it significantly reduced the prevalence of hookworm, Trichuris, Ascaris, 
S.japonicum and S.mansoni. There was no impact of mass deworming during pregnancy haemoglobin, birth 
weight, low birth weight, preterm birth, perinatal mortality, stillbirths, neonatal mortality and congenital 
abnormalities. Findings from the systematic review on interventions other than mass deworming among 
pregnant women and WRA on maternal, birth and newborn health outcomes suggests that the data are too 
scarce and of low quality. The individual participant data meta-analysis (IPD) to explore whether the effect of 
mass deworming during pregnancy varies with individual characteristics, intensity of infection, infection 
status, socioeconomic status, sanitation environment and co-interventions analyzes majority of the existing 
data (70% of the total potential participant population). Findings from the IPD analysis suggest that mass 
deworming during pregnancy is associated with reducing anaemia with no apparent impact on infection 
intensity, low birth weight and preterm birth. These analyses were limited by the availability of data for the 
impact by subgroups and effect modification. Further studies accounting for maternal baseline worm 
intensities, concomitant iron/folic acid supplementation and antenatal care coverage could change our 










Summary of main results 
Findings from the systematic review assessing mass deworming during pregnancy suggests that it does not 
have any impact on maternal anemia; however it significantly reduced the prevalence of hookworm, Trichuris, 
Ascaris, S.japonicum and S.mansoni. There was no impact of mass deworming during pregnancy 
haemoglobin, birth weight, low birth weight, preterm birth, perinatal mortality, stillbirths, neonatal mortality 
and congenital abnormalities. Findings from the systematic review on interventions other than mass 
deworming among pregnant women and WRA on maternal, birth and newborn health outcomes suggests 
that the data are too scarce and of low quality.  
The IPD meta-analysis is based on the data from three trials with 5957 participants. Findings from this IPD 
suggest reduction in anaemia among pregnant women with mass deworming. There was no evidence of 
effect on any of the other outcomes including Trichiura infection, hookworm infection or any of the pregnancy 
outcomes including LBW and preterm birth. Findings of no impact of mass deworming on infection intensity 
could be attributable to the fact that majority of the study population in the included studies were either not 
infected or lightly infected which could have diluted the impact. Based on the availability of the data, we could 
only assess for effect modification by baseline Trichiura infection, maternal anemia at baseline and maternal 
BMI at baseline. There was no evidence of effect modification by Trichiura intensity at baseline, maternal 
anemia at baseline and maternal BMI at baseline; however we advise caution in interpreting these findings 
due to limited number of participants included in the analysis.  
Overall completeness and applicability of evidence 
Findings from this IPD analysis are based on 70% of the existing data deemed eligible for IPD (5957 
participants of 8515 participants). The studies included in this review were conducted among pregnant 
women in LMIC settings. One of the three trials included in the IPD analysis provided daily iron folate 
supplements (36mg iron; 5mg folate) along with the deworming drugs. We conducted an extensive search of 
electronic databases. We screened 23,406 articles and updated this search to March 2018. We report the 
systematic review according to the reporting guidelines for IPD and systematic review and meta-analysis 
(PRISMA and PRISMA-IPD). We published and followed an a priori protocol (Salam, Middleton et al.). Our 
systematic review and IPD analysis was approved by the Research Ethics Boards at SickKids. We developed 
a data sharing agreement that was signed by all studies that contributed data. Study authors were invited to 
join the Investigator’s Collaborative, participate in meetings and contribute to the final report. Our process 
and conduct of the IPD was driven by consultation with our expert Advisory board which included statistical, 
parasitology and nutrition expertise.   
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Quality of the evidence 
The trials included in the systematic review and IPD were judged to be of fairly good quality. All of the included 
studies were judged to be at low risk of bias for blinding of participants, personnel and outcome assessor; 
and selective reporting. One of the included studies was judged to be at high risk of bias for allocation 
concealment while two studies were at high risk for attrition bias. The overall outcome quality was judged to 
‘moderate’ based on the GRADE criteria. The outcome quality was downgraded due to study limitations since 
the estimates are based on selected sample eligible for IPD. 
Limitations and potential biases in the review process 
Despite of receiving majority of the existing data (70%) to conduct IPD, there were a few limitations. One 
limitation of this review is that we did not receive data from all eligible studies. Another limitation is that we 
were unable to assess effect modification by pre-identified effect modifiers. The trials did not capture many 
of the variables of interest that restricted our analysis. Very few trials reported outcomes according to the 
baseline level of infection intensities and hence those conclusions could not be drawn. In terms of the 
infection intensities, the population studied were either not infected or lightly infected and hence it was difficult 
to categorize the sample according to the intensity of infection and have meaningful estimates. Trials did not 
report baseline data on the individual and environmental level effect modifiers and hence it was difficult to 
assess the effect modification. Variables like socio-economic status were least studied and where reported, 
had different definitions and hence could not be accounted for. None of the included studies assessed any 
co-interventions including WASH practices and hence the impact of co-interventions could not be assessed. 
We could not assess for publication bias given the small number of included studies; however, considering 
the small universe of studies in the domain, the issues related to publication and small study sizes cannot be 
ignored.  
Agreements and disagreements with other studies or reviews 
The most recent Cochrane meta-analysis (Salam, Haider et al. 2015) on deworming for STH during 
pregnancy concluded that there was insufficient evidence to recommend deworming for STH. This review 
also highlighted the need for future well-designed, large scale RCTs to establish the benefit. These findings 
were based on four trials including 4265 participants. This review has some differences compared to our 
review. The inclusion criteria for this Cochrane review was limited to deworming for STH alone while our IPD 
meta-analysis also included trials with deworming for schistosomiasis. The Cochrane review reported no 
impact of mass deworming for STH on maternal anaemia while findings from our review suggests reduction 
in maternal anaemia associated with mass deworming. 
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Implications for policy 
This systematic review and IPD suggest that mass deworming reduces maternal anemia with moderate 
quality evidence. The existing deworming guidelines clearly specify the geographic prevalence cut-offs for 
mass deworming implementation; however, it does not take into account the infection intensities among 
various population groups and the existing deworming coverage. There is a need to built-in these guidelines 
in existing deworming policies. Moreover, deworming alone is insufficient to achieve improvements in all 
maternal and newborn health outcomes. These findings reinforce that it is essential to focus on sustainable 
development to address the other factors such as poor sanitation, food insecurity and malnutrition. Mass 
deworming should be bundled as part of these packages to improve range of maternal and newborn health 
outcomes. 
Implications for research 
There is a need to evaluate mass deworming for STH and schistosomiasis during pregnancy in large scale 
programmatic settings. Future impact evaluations should attempt to measure various individual and 
environmental factors that could potentially affect the impact of mass deworming. Future program evaluations 
should also assess the long term impact of mass deworming on birth and infant health outcomes along with 
the maternal health outcomes. Safety of mass deworming for the various subgroups of WRA, except pregnant 
women also need to be studied. There is a need to broaden the scope of research to investigate the cost-
effectiveness and feasibility of alternative treatment strategies in achieving the interruption of transmission 
across a range of settings. There is an urgent need for open data from all research studies. The quality of 
evidence is rated as moderate for our findings and further research on maternal baseline worm intensities 











Appendix 1: Search Strategy 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)  
1     flukes.tw. 33     Albendazole/  65     Oxamniquine.tw.  
2     platyhelminth*.tw.  34     Mebendazole/ 66     Praziquantel/  
3     whipworm*.tw.  35     exp Piperazines/ 67     Trichlorfon/ 
4     whip worm*.tw. 36     Levamisole/  68     metrifonate.tw. 
5     hookworm*.tw.  37     exp Pyrantel/  69     Artemisinins/  
6     hookworm*.tw.  38     Ivermectin/  70     (artesunate or 
artemether).tw.  
7     hook worm*.tw.  39     exp Anthelmintics/  71     or/34-72  
8     roundworm*.tw.  40     Ivermectin.tw.  72     (deworm* or de-
worm*).tw. 
9     round worm*.tw.  41     Albendazole.tw.  73     exp Anthelmintics/ or 
(anthelmint* or 
antihelmint*).tw. 
10     geohelminth*.tw.  42     Mebendazole.tw.  74     72 or 73  
11     ancylostoma*.tw.  43     Piperazine*.tw. 75     Pregnant Women/ or 
Pregnancy/ or Pregnancy 
Complications, Parasitic/ 
pregnant wom*n .tw.  
12     Necator*.tw.  44     Levamisole.tw. 76     32 and 71 
13     Ascaris.tw.  45     pyrantel.tw.  77     74 or 76 
14     Ascaridida.tw.  46     tiabendazole.tw. 78     75 and 77 
15     Ancylostoma.tw.  47     anthelmint*.tw.  
16     Necator americanus.tw. 48     Anticestodal.tw.   
17     Trichuris.tw.  49     Antiplatyhelmintic.tw.  
18     Trichuroidea.tw.  50     Anti-platyhelmintic.tw.  
19     Adenophorea.tw. 51     Albendazole.tw.   
20     Enoplida.tw. 52     Dichlorophen.tw.  
21     Ascaridida.tw.  53     Niclosamide.tw.   
22     Platyhelminth*.tw.  54     Bithionol.tw.   
23     Rotifera.tw.  55     Diamfenetide.tw.   
24     trichuriasis.tw.  56     Nitroxinil.tw.  
25     ascariasis.tw.  57     Oxyclozanide.tw.  
26     ancylostomiasis.tw.  58     Rafoxanide.tw.   
27     ascarid*.tw.  59     Schistosomicid*.tw.   
28     schistosom*.tw.  60     Antimony Potassium 
Tartrate.tw.  
 
29     bilharziosis.tw. 61     Antimony Sodium 
Gluconate.tw. = 
 
30     bilharzia*.tw.  62     Hycanthone.tw.  
31     exp Schistosoma/  63     Lucanthone.tw.   
32     or/1-31  64     Niridazole.tw.   
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Database: Embase Classic+Embase 
1     whipworm*.tw.  31     Secernentea.tw.  61     Piperazine*.tw.  91     (woman or women).tw. 
2     whip worm*.tw.  32     Ascaridida.tw.  62     Levamisole.tw. 92     pregnan*.tw.  
3     hookworm*.tw.  33     Rhabditida.tw.  63     pyrantel.tw.  93     or/90-92 
4     hookworm*.tw.  34     Cestoda.tw.  64     tiabendazole.tw.  94     50 and 85  
5     hook worm*.tw.  35     Trematod*.tw.  65     anthelmint*.tw.  95     94 or 89 
6     roundworm*.tw.  36     Turbellaria.tw.  66     *Antiplatyhelmintic 
Agents/  
96     95 and 93  
7     round worm*.tw.  37     Platyhelminth*.tw.  67     Anticestodal.tw.   
8     pinworm*.tw. 38     Rotifera.tw.  68     Antiplatyhelmintic.tw.  
9     pin worm*.tw.  39     trichuriasis.tw.  69     Anti-platyhelmintic.tw.  
10     flukes.tw.  40     ascariasis.tw.  70     Albendazole.tw.   
11     geohelminth*.tw.  41     trichinellosis.tw.  71     Dichlorophen.tw.   
12     ancylostoma.tw.  42     
Trichostrongyloidiasis.tw.  
72     Niclosamide.tw.   
13     Necator*.tw.  43     ancylostomiasis.tw.  73     Bithionol.tw.   
14     Ascaris.tw.  44     enterobiasis.tw.  74     Diamfenetide.tw.   
15     Ascaridida.tw.  45     cestode*.tw.  75     Nitroxinil.tw.   
16     Ancylostoma.tw.  46     trematode*.tw.  76     Oxyclozanide.tw.   
17     Necator 
americanus.tw.  
47     ascarid*.tw.  77     Rafoxanide.tw.   
18     Enterobius.tw.  48     schistosomiasis.tw.  78     Schistosomicide*.tw.   
19     Oxyuroidea.tw.  49     Schistosoma*.tw.  79     Antimony Potassium 
Tartrate.tw.  
 
20     Oxyurida.tw.  50     or/1-49  80 Antimony Sodium 
Gluconate.tw. 
 
21     Trichuris.tw.  51     Albendazole/  81     Hycanthone.tw.  
22     Trichuroidea.tw.  52     Mebendazole/  82     Lucanthone.tw.  
23     Capillaria.tw.  53     exp Piperazines/  83     Niridazole.tw.   
24     Trichinella.tw.  54     Levamisole/  84     Oxamniquine.tw.  
25     Strongyloid*.tw. 55     exp Pyrantel/  85     or/51-84  
26 Oesophagostomum.tw.  56     Ivermectin/  86     (deworm* or de-
worm*).tw.  
 
27 Oesophagostomiasis.tw. 57     exp Anthelmintics/  87     anthelmint*.tw.  
28     Acanthocephala.tw.  58     Ivermectin.tw.  88     anthelmintic/  
29     Adenophorea.tw.  59     Albendazole.tw.  89     or/86-88   





Cochrane Library – CDSR, DARE, CENTRAL, EED, HTA 
ID Search 
#1 helmint*:ti,ab,kw  (Word variations have been searched) #17 piperazine 
#2 Ancylostoma duodenale  #18 levamisole  
#3 Necator americanus  #19 pyrantel 
#4 Ascaris  #20 tiabendazole   
#5 Enterobius vermicularis  #21 deworm*:ti,ab or de-worm*:ti,ab 
#6 trichuris  #22 #15 or #16 or #17 or #18 or #19 
or #20 or #21  
#7 Strongyloid*  #23 #21 or #22  
#8 hookworm*  #24 #23 and #14  
#9 roundworm*  #25 deworm  
#10 pinworm*  #26 de-worm 
#11 whipworm*  #27 deworming  
#12 schistosomiasis  #28 de-worming 
#13 Schistosoma  #29 anthelmint*  
#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 
or #11 or #13  
#30 anthelmintic 
#15 albendazole  #31 #25 or #26 or #27 or #28 or #29 
or #30 

























Appendix 2: Characteristics of the Excluded Studies 
Studies Reason for Exclusion 
(Basra et al., 2012) This study did not report any of the maternal, pregnancy or newborn 
health outcomes.  
(Christian, Shahid, Rizvi, 
Klemm, & Bhutta, 2009) 
This study compared different regimens of anti-helminthic treatment 
(single dose versus 3 days mebendazole) with appropriate control 
group.  
(Nery et al., 2015) This study assessed the anti-helminthic efficacy of a single dose of 
albendazole in communities and does not specifically targets pregnant 
women 
(Insetta, Soriano, Totañes, 
Macatangay, & Belizario Jr, 
2014) 
This study qualitatively assessed the perceptions related to deworming 
during pregnancy. 
(Boel et al., 2010) This study assessed associations between STH and malaria infections 
among pregnant women. 
(Casey et al., 2009) This study assessed the effectiveness of deworming among women 
disregarding their pregnancy status. 
(Ivan et al., 2014) This study assessed deworming during pregnancy among HIV-
infected women. 
(Passerini et al., 2012) This study assessed the effectiveness of pre-pregnancy deworming. 
(Drevfuss et al., 1996) This study assessed association between iron status and STH 
infection during pregnancy. 
(Casey et al., 2011) This study assessed the cost effectiveness of deworming for WRA 













Appendix 3: Search Strategy 
MEDLINE 
1. ((exp water quality/ or exp water supply/ or exp water purification/ or exp filtration/ or (water adj2 
stor*).tw.) and (consum* or drink*).mp.) or exp drinking water/ or potable water.mp. or ((household 
adj2 treatment).tw. and water.mp.) 
2. ((exp groundwater/ or groundwater.tw.) and (suppl* or drink* or consum* or contamin*.mp.)).tw. or 
((exp water pollutants/ or exp water pollution/) and ((consum* or suppl*).mp. or drink*.tw.)) 
3. (exp toilet facilities/ or exp sanitation/ or exp waste water/ or toilet*.tw. or latrine*.mp. or 
sanitation*.tw. or standpipe*.tw. or sewer*.tw. or excreta.tw. or open defecation.tw.) and health.tw. 
4. (exp hygiene/ or hygien*.mp. or (health and sanitation and education).mp. or (wash adj1 (hand 
disinfection or hand hygiene or hand*)).mp. or hygiene behavio?r.tw.) and (child* or baby or newborn 
or infant or neonat* or infant).tw. and (interven* or compar* or control*).mp. 
5. (wom*n or WRA or pegnan* or girl* or adolescen*) 
6. 1 or 2 or 3 or 4 












Appendix 4: Characteristics of the Excluded Studies  
Studies Reasons for Exclusion  
(Abebe, Kiros, Golasa, & Zeynudin, 2010) This study did not report separate findings for WRA. 
(Bella, de C. Marshall, Omer, & Vaughan, 1980) This study did not report separate findings for WRA. 
(Chandiwana, 1987) This study did not report separate findings for WRA. 
(Couto et al., 2014) This study did not report separate findings for WRA. 
(Gazzinelli et al., 2001) This study did not report separate findings for WRA. 
(Ghebreyesus et al., 2002) This study did not report separate findings for WRA. 
(Dalton & Pole, 1978) This study did not report separate findings for WRA. 
(Lima e Costa et al., 1991) This study did not report separate findings for WRA. 
(Firmo, Costa, Guerra, & Rocha, 1996) This study did not report separate findings for WRA. 
(Gazzinelli et al., 2006) This study did not report separate findings for WRA. 
(Kloos et al., 2006) This study assessed the methods for assessing water contact. 
(Kloos, Quites, Oliveira, LoVerde, & Gazzinelli, 2012) This study assessed the methods for assessing water contact. 
(Kvale, 1981) This study did not report separate findings for WRA. 
(Matthys et al., 2007) This study did not report separate findings for WRA. 
(de Moira, Kabatereine, Dunne, & Booth, 2011) This study did not report separate findings for WRA. 
(Mota & Sleigh, 1987) This study did not report separate findings for WRA. 
(Mwanga & Lwambo, 2013) This study did not report separate findings for WRA. 
(Ndassa, Mimpfoundi, Gake, Paul Martin, & Poste, 2007) This study did not report separate findings for WRA. 
(Ngui et al., 2015) This study did not report separate findings for WRA. 
(Ofoezie, Christensen, & Madsen, 1998) This study only assessed various water contacts. 
(Paredes et al., 2010) This study did not report separate findings for WRA. 
(Pham-Duc et al., 2013) This study did not report separate findings for WRA. 
(Phongluxa et al., 2013) This study did not report separate findings for WRA. 
(Schmidlin et al., 2013) This study did not report separate findings for WRA. 
(Schüle et al., 2014) This study did not report separate findings for WRA. 
(Taylor, Chandiwana, Govere, & Chombo, 1987) This study did not report separate findings for WRA. 
(Tefera & Mebrie, 2014) This study did not report separate findings for WRA. 
(Trang, Mølbak, Cam, & Dalsgaard, 2007) This study did not report separate findings for WRA. 
(Trönnberg, Hawksworth, Hansen, Archer, & Stenström, 2010) This study did not report separate findings for WRA. 
(Bethony et al., 2001) This study did not report separate findings for WRA. 
(Useh & Ejezie, 1999) This study did not report separate findings for WRA. 
(Wilkins, Blumenthal, Hagan, Hayes, & Tulloch, 1987) This study did not report separate findings for WRA. 
(Yajima et al., 2009) This study did not report separate findings for WRA. 
(Traub, Robertson, Irwin, Mencke, & Thompson, 2004) This study did not report separate findings for WRA. 
(Hidayah, Teoh, & Hillman, 1997) This study did not report separate findings for WRA. 
(Corrales, Izurieta, & Moe, 2006) This study did not report separate findings for WRA. 
(Knopp et al., 2013) This study did not report separate findings for WRA. 
(Mahmud et al., 2013) This study did not report separate findings for WRA. 
(Parajuli, Umezaki, & Watanabe, 2009) This study did not report separate findings for WRA. 
(Gunawardena, Karunaweera, & Ismail, 2004) This study did not report separate findings for WRA. 
(Balen et al., 2011) This study did not report separate findings for WRA. 
(Humphries et al., 2011) This study did not report separate findings for WRA. 
(Jiraanankul et al., 2011) This study did not report separate findings for WRA. 
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Appendix 5: Search Strategy 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)  
1     flukes.tw. 41     Albendazole.tw.  
2     platyhelminth*.tw.  42     Mebendazole.tw.  
3     whipworm*.tw.  43     Piperazine*.tw. 
4     whip worm*.tw. 44     Levamisole.tw. 
5     hookworm*.tw.  45     pyrantel.tw.  
6     hookworm*.tw.  46     tiabendazole.tw. 
7     hook worm*.tw.  47     anthelmint*.tw. 
8     roundworm*.tw.  48     Anticestodal.tw.  
9     round worm*.tw.  49     Antiplatyhelmintic.tw. 
10     geohelminth*.tw.  50     Anti-platyhelmintic.tw. 
11     ancylostoma*.tw.  51     Albendazole.tw.  
12     Necator*.tw.  52     Dichlorophen.tw. 
13     Ascaris.tw.  53     Niclosamide.tw.  
14     Ascaridida.tw.  54     Bithionol.tw.  
15     Ancylostoma.tw.  55     Diamfenetide.tw.  
16     Necator americanus.tw. 56     Nitroxinil.tw. 
17     Trichuris.tw.  57     Oxyclozanide.tw. 
18     Trichuroidea.tw.  58     Rafoxanide.tw.  
19     Adenophorea.tw. 59     Schistosomicid*.tw.  
20     Enoplida.tw. 60     Antimony Potassium Tartrate.tw.  
21     Ascaridida.tw.  61     Antimony Sodium Gluconate.tw. = 
22     Platyhelminth*.tw.  62     Hycanthone.tw. 
23     Rotifera.tw.  63     Lucanthone.tw.  
24     trichuriasis.tw.  64     Niridazole.tw.  
25     ascariasis.tw.  65     Oxamniquine.tw.  
26     ancylostomiasis.tw.  66     Praziquantel/  
27     ascarid*.tw.  67     Trichlorfon/ 
28     schistosom*.tw.  68     metrifonate.tw. 
29     bilharziosis.tw. 69     Artemisinins/  
30     bilharzia*.tw.  70     (artesunate or artemether).tw.  
31     exp Schistosoma/  71     or/34-72  
32     or/1-31  72     (deworm* or de-worm*).tw. 
33     Albendazole/  73     exp Anthelmintics/ or (anthelmint* or 
antihelmint*).tw. 
34     Mebendazole/ 74     72 or 73  
35     exp Piperazines/ 75     Pregnant Women/ or Pregnancy/ or Pregnancy 
Complications, Parasitic/ pregnant wom*n .tw.  
36     Levamisole/  76     32 and 71 
37     exp Pyrantel/  77     74 or 76 
38     Ivermectin/  78     75 and 77 
39     exp Anthelmintics/   




Database: Embase Classic+Embase 
1     whipworm*.tw.  51     Albendazole/  
2     whip worm*.tw.  52     Mebendazole/  
3     hookworm*.tw.  53     exp Piperazines/  
4     hookworm*.tw.  54     Levamisole/  
5     hook worm*.tw.  55     exp Pyrantel/  
6     roundworm*.tw.  56     Ivermectin/  
7     round worm*.tw.  57     exp Anthelmintics/  
8     pinworm*.tw. 58     Ivermectin.tw.  
9     pin worm*.tw.  59     Albendazole.tw.  
10     flukes.tw.  60     Mebendazole.tw.  
11     geohelminth*.tw.  61     Piperazine*.tw.  
12     ancylostoma.tw.  62     Levamisole.tw. 
13     Necator*.tw.  63     pyrantel.tw.  
14     Ascaris.tw.  64     tiabendazole.tw.  
15     Ascaridida.tw.  65     anthelmint*.tw.  
16     Ancylostoma.tw.  66     *Antiplatyhelmintic Agents/  
17     Necator americanus.tw.  67     Anticestodal.tw.  
18     Enterobius.tw.  68     Antiplatyhelmintic.tw. 
19     Oxyuroidea.tw.  69     Anti-platyhelmintic.tw. 
20     Oxyurida.tw.  70     Albendazole.tw.  
21     Trichuris.tw.  71     Dichlorophen.tw.  
22     Trichuroidea.tw.  72     Niclosamide.tw.  
23     Capillaria.tw.  73     Bithionol.tw.  
24     Trichinella.tw.  74     Diamfenetide.tw.  
25     Strongyloid*.tw. 75     Nitroxinil.tw.  
26     Oesophagostomum.tw.  76     Oxyclozanide.tw.  
27     Oesophagostomiasis.tw. 77     Rafoxanide.tw.  
28     Acanthocephala.tw.  78     Schistosomicide*.tw.  
29     Adenophorea.tw.  79     Antimony Potassium Tartrate.tw.  
30     Enoplida.tw.  80     Antimony Sodium Gluconate.tw.  
31     Secernentea.tw.  81     Hycanthone.tw. 
32     Ascaridida.tw.  82     Lucanthone.tw. 
33     Rhabditida.tw.  83     Niridazole.tw.  
34     Cestoda.tw.  84     Oxamniquine.tw. 
35     Trematod*.tw.  85     or/51-84 
36     Turbellaria.tw.  86     (deworm* or de-worm*).tw.  
37     Platyhelminth*.tw.  87     anthelmint*.tw. 
38     Rotifera.tw.  88     anthelmintic/ 
39     trichuriasis.tw.  89     or/86-88  
40     ascariasis.tw.  90     pregnant wom*n .tw. 
41     trichinellosis.tw.  91     (woman or women).tw. 
42     Trichostrongyloidiasis.tw.  92     pregnan*.tw.  
43     ancylostomiasis.tw.  93     or/90-92 
44     enterobiasis.tw.  94     50 and 85  
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45     cestode*.tw.  95     94 or 89 
46     trematode*.tw.  96     95 and 93  
47     ascarid*.tw.   
48     schistosomiasis.tw.   
49     Schistosoma*.tw.   





Cochrane Library – CDSR, DARE, CENTRAL, EED, HTA 
ID Search  
#1 helmint*:ti,ab,kw  (Word variations have been searched) 
#2 Ancylostoma duodenale  
#3 Necator americanus  
#4 Ascaris  
#5 Enterobius vermicularis  
#6 trichuris  
#7 Strongyloid*  
#8 hookworm*  
#9 roundworm*  
#10 pinworm*  
#11 whipworm*  
#12 schistosomiasis  
#13 Schistosoma  
#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #13  
#15 albendazole  
#16 mebendazole  
#17 piperazine  
#18 levamisole  
#19 pyrantel  
#20 tiabendazole  
#21 deworm*:ti,ab or de-worm*:ti,ab  
#22 #15 or #16 or #17 or #18 or #19 or #20 or #21  
#23 #21 or #22  
#24 #23 and #14  
#25 deworm  
#26 de-worm  
#27 deworming  
#28 de-worming  
#29 anthelmint*  
#30 anthelmintic  
#31 #25 or #26 or #27 or #28 or #29 or #30 
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